[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 419
1. Schuette W: Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer; 2001 Sep;33 Suppl 1:S99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as treatment of primary and recurrent small cell lung cancer.
  • Chemotherapy is the treatment of choice in metastatic stage of small-cell lung cancer (SCLC).
  • Radiation therapy, surgery and other forms of therapy are only included in special treatment situations, particularly for different local problems.
  • A wide range of chemotherapeutic agents have proven to be effective in SCLC, including carboplatin, cisplatin, cyclophosphamide, doxorubicin, epirubicin, etoposide, ifosfamide, teniposide and vincristine.
  • However, treatment results could not be improved over the last 10 years and the median survival of patients with metastatic disease is limited to 7-10 months.
  • Yet, no evidence is provided from randomized trials to employ these drugs in first line treatment.
  • Clearly, polychemotherapy is superior to single agent treatment.
  • Neither extending the initial treatment beyond the median number of six cycles, nor maintenance treatment have-so far-resulted in any increase in survival results for patients with metastasised SCLC.
  • Brain metastases represent a high frequent complication associated with SCLC.
  • In these cases, the combination of chemotherapy and whole brain radiation therapy is advocated.
  • Second-line treatment should always be considered in patients with relapse or failure to first-line therapy.
  • In addition to a rechallenging with the prior drug combination or selecting a different potentially non-cross resistant one, monotherapy with topotecan proved to be effective as well.
  • In summary, up to now, no standard chemotherapy combination exists for metastatic SCLC.
  • The individual therapy strategy can only be selected by considering the clinically relevant conditions of the patient.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11576714.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 74
  •  go-up   go-down


2. Schild SE, Bonner JA, Hillman S, Kozelsky TF, Vigliotti AP, Marks RS, Graham DL, Soori GS, Kugler JW, Tenglin RC, Wender DB, Adjei A: Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol; 2007 Jul 20;25(21):3124-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
  • PURPOSE: To evaluate the outcome of patients with limited-stage small-cell lung cancer (L-SCLC) treated with cisplatin and etoposide (PE), early prophylactic cranial irradiation (PCI), and high-dose twice-daily thoracic radiotherapy (bid RT).
  • PCI (25 Gy/10 fractions) was delivered during cycle 3 to responding patients.
  • Cycles 4 and 5 included concurrent chemotherapy and thoracic RT (30 Gy/20 bid fractions, a 2-week break, and another 30 Gy/20 bid fractions).
  • Only one (2%) of the 61 patients who received PCI experienced treatment failure in the brain.
  • The 5-year cumulative incidence of in-field treatment failure was 34%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / therapy. Lung Neoplasms / mortality. Lung Neoplasms / therapy. Radiotherapy, High-Energy / methods
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Etoposide / administration & dosage. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol; 2002 Nov 15;20(22):4434-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
  • PURPOSE: Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC).
  • This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy.
  • PATIENTS AND METHODS: SCLC patients in complete or partial remission were eligible.
  • They were stratified by radiotherapy (early, late, or none), stage (extensive or limited), response (complete or partial), and cooperative group (National Cancer Institute of Canada-Clinical Trials Group or European Organization for Research and Treatment of Cancer).
  • Stage was limited for 279 patients (52%) and extensive for 253 (48%).
  • Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection.
  • The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P =.81).
  • Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P =.90) Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat).
  • CONCLUSION: Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Small Cell / drug therapy. Enzyme Inhibitors / therapeutic use. Hydroxamic Acids / therapeutic use. Lung Neoplasms / drug therapy. Metalloendopeptidases / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Canada. Double-Blind Method. Europe. Female. Humans. Male. Middle Aged. Patient Compliance. Proportional Hazards Models. Prospective Studies. Quality of Life. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Treat Rev. 2003 Apr;29(2):127-9 [12670456.001]
  • (PMID = 12431965.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-28; United States / NCI NIH HHS / CA / 5U10 CA11488-29; United States / NCI NIH HHS / CA / 5U10CA11488-27
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Hydroxamic Acids; D5EQV23TDS / marimastat; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


Advertisement
4. Rizzo JD, Elias AD, Stiff PJ, Lazarus HM, Zhang MJ, Oblon DJ, Pecora AL, Hale GA, Horowitz MM: Autologous stem cell transplantation for small cell lung cancer. Biol Blood Marrow Transplant; 2002;8(5):273-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for small cell lung cancer.
  • Small cell lung cancer usually responds to radiation and chemotherapy, but cures are infrequent.
  • Autotransplantation attempts to increase cures by intensifying the effects of chemotherapy.
  • We studied 103 patients receiving high-dose chemotherapy with autologous hematopoietic stem cell transplantation (SCT) for small cell lung cancer in 1989-1997 at 22 centers participating in the Autologous Blood and Marrow Transplant Registry.
  • Median time from diagnosis to transplantation was 6 months (range, 1-34 months).
  • Most patients underwent transplantation after partial response (66%) or complete response (27%) to combination therapy.
  • Factors negatively associated with outcome in multivariate analysis were age greater than 50 years, extensive-stage disease at presentation, and preparative regimens other than CBP or ICE.
  • Three-year survival and PFS rates were higher in patients with limited versus extensive disease, 43% versus 10% (P < .001) and 35% versus 4% (P < .001), respectively.
  • Autologous SCT produces long-term survival in some patients with small cell lung cancer; SCT outcomes appear better in young patients with limited-stage disease.
  • Transplantation for patients with extensive disease does not appear to produce substantial benefit.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Hematopoietic Stem Cell Transplantation / statistics & numerical data

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12064365.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / CP-21161; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G: Small cell lung cancer. Ann Oncol; 2006 Mar;17 Suppl 2:ii5-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell lung cancer.
  • Small cell lung cancer accounts for 13-15% of all lung cancer worldwide.
  • In the early eighties, it became clear that SCLC was an extremely sensitive tumor as to radiation as to chemotheraputic agents.
  • With cisplatinum etoposide combinations or cyclophosphamide, anthracycline and vincristine/etyoposide regimens responses were observed in 50-70%, with 20-30% complete remissions in extensive disease.
  • For limited stage patients chemotherapy associated with thoracic radiation was able to produce a cure rate of 10-20%.
  • The addition of prophylactic brain irradiation to limited stage cases has reduced mortality by a factor of nearly 5%.
  • New agents have recently been included in the therapeutic armamentarium, such as gemcitabine, irinotecan, paclitaxel.
  • This fact has allowed many patients to receive a relatively active second line therapy, but the overall survival remains unchanged.
  • Targeted therapies are undergoing some evaluations, but the data are too premature and so far quite discouraging.
  • At the present time there is a urgent need to improve clinical research in this somehow forgotten disease.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608983.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


6. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS: Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer; 2003 Jul;5(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
  • The combination of IP (irinotecan/cisplatin) has been shown to confer a survival benefit compared with EP (etoposide/cisplatin) in patients with extensive-stage small-cell lung cancer (SCLC).
  • Based on this and potential synergy from sequential inhibition of topoisomerases I and II, we conducted a phase I study to assess the feasibility of weekly therapy alternating IP and EP.
  • Patients with limited-stage SCLC received chemoradiation during weeks 4-6 with etoposide 120 mg/m2 on days 1-3, cisplatin 60 mg/m2 on day 1, and thoracic radiation 1.5 Gy twice daily in 30 fractions.
  • Patients received 12 weeks of therapy.
  • To evaluate dose escalation in subsequent cohorts, dose-limiting toxicity (DLT) was initially assessed during weeks 1-3 of treatment.
  • Characteristics of the 18 patients accrued are as follows: performance status 0/1, n = 9; female sex, n = 9; extended-stage SCLC, n = 16; and median age, 53 years.
  • Four patients treated at irinotecan dose level 1 (80 mg/m2), 6 patients at dose level 2 (90 mg/m2), and 6 patients at dose level 3 (100 mg/m2) did not experience DLT in weeks 1-4 and completed therapy without major incident.
  • However, patients had already been accrued at dose level 3 and tolerated therapy well.
  • With the exception of the 2 deaths, the therapy was well tolerated and active.
  • Phase II evaluation of the regimen in patients with extensive-stage SCLC is ongoing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Maximum Tolerated Dose. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14596703.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Munzuroglu F, Erturan S, Oz B, Dincbas FO, Demir G: Non small cell lung cancer within the small cell lung cancer radiotherapy field after 11 years. J BUON; 2009 Apr-Jun;14(2):313-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non small cell lung cancer within the small cell lung cancer radiotherapy field after 11 years.
  • A 71-year-old male was diagnosed with a non-small cell lung cancer (NSCLC) within the radiotherapy field that was used for the treatment of a small cell lung cancer (SCLC) 11 years ago.
  • At the initial diagnosis in 1996 the patient had limited-stage SCLC located in the right upper lobe of the lung with mediastinal involvement.
  • He received 4 cycles of chemotherapy and then mediastinal radiotherapy.
  • With a complete response after chemoradiotherapy he was given prophylactic cranial radiotherapy.
  • After 11 years of disease-free period a new mass in left lower lobe of the lung was detected.
  • Bronchoscopic biopsy showed second lung cancer with epidermoid histology.
  • Although the incidence of a second lung cancer is higher in SCLC survivors, this is a unique case in the literature with second NSCLC developing in the previously irradiated side of limited-stage SCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / etiology. Lung Neoplasms / diagnosis. Neoplasms, Second Primary / etiology. Small Cell Lung Carcinoma / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Cranial Irradiation. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650185.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer; 2004 Feb;43(2):223-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer.
  • An evidence-based practice guideline was developed to identify the optimal combination chemotherapy regimen, schedule of administration, and duration of therapy for the first-line treatment of adults with limited-stage small-cell lung cancer.
  • If bolus etoposide-cisplatin is the treatment of choice, evidence from one randomized trial suggests that the optimal sequence of administration is cisplatin followed by etoposide.
  • The use of maintenance chemotherapy is not indicated.
  • There is insufficient evidence to support the routine use of dose-intensive regimens outside a clinical trial, to determine the optimal duration of chemotherapy, or to support the routine substitution of carboplatin for cisplatin in combination chemotherapy regimens in this patient population.
  • RECOMMENDATIONS: Etoposide-cisplatin is the preferred chemotherapy regimen for patients with limited-stage small-cell lung cancer when concurrent thoracic radiotherapy is used.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Evidence-Based Medicine. Humans. Prognosis. Randomized Controlled Trials as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14739044.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Guideline; Journal Article; Meta-Analysis; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


9. Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, Vincent MD, Yu EW: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol; 2003 Apr 15;21(8):1544-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival.
  • PURPOSE: To determine the impact of continued smoking by patients receiving chemotherapy (CHT) and radiotherapy (RT) for limited-stage small-cell lung cancer (LSCLC) on toxicity and survival.
  • Treatment consisted of six cycles of alternating cyclophosphamide, doxorubicin, vincristine and etoposide, cisplatin (EP).
  • RT interruption during concurrent CHT/RT was used as the marker for treatment toxicity.
  • RT interruptions were recorded in 38 patients (20.5%), with a median duration of 5 days (range, 1 to 18 days).
  • Continuing smokers did not have a greater incidence of toxicity-related treatment breaks (P =.49), but those who continued to smoke and also experienced a treatment break had the poorest overall survival (median, 13.4 months; log-rank P =.0014).
  • Smoking did not have an impact on the rate of treatment interruptions attributed to toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / therapy. Lung Neoplasms / mortality. Lung Neoplasms / therapy. Smoking / adverse effects. Smoking / mortality
  • [MeSH-minor] Actuarial Analysis. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12697879.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ohe Y, Saijo N: Topoisomerase I targeting agents in small-cell lung cancer. Curr Oncol Rep; 2001 Mar;3(2):170-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase I targeting agents in small-cell lung cancer.
  • The topoisomerase I inhibitors such as irinotecan and topotecan are active agents against small-cell lung cancer that are effective in treating not only chemotherapy-naïve tumors but also progressed-stage tumors after treatment with cisplatin-based regimens, because their mechanism of antitumor activity differs from that of the agents included in standard chemotherapy for small-cell lung cancer.
  • Etoposide plus cisplatin or etoposide plus cisplatin alternating with cyclophosphamide, doxorubicin, and vincristine is considered the standard regimen for small-cell lung cancer.
  • No new standard combination chemotherapy for small-cell lung cancer has been developed over the past decade.
  • Irinotecan with cisplatin is now established as a new standard chemotherapy for extensive-stage small-cell lung cancer based on the results of the Japan Clinical Oncology Group trial.
  • The Japan Clinical Oncology Group is intensively investigating other irinotecan-containing regimens and the incorporation of irinotecan into treatment of patients with limited-stage small-cell lung cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Topoisomerase I Inhibitors
  • [MeSH-minor] Combined Modality Therapy. DNA Topoisomerases, Type I / metabolism. Humans. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1993 Feb;84(2):203-7 [8385085.001]
  • [Cites] J Clin Oncol. 1992 Aug;10 (8):1225-9 [1321891.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):647-56 [1312588.001]
  • [Cites] J Natl Cancer Inst. 1991 Aug 21;83(16):1164-8 [1653362.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2194-204 [8229134.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1964-5 [8656268.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1310-5 [7882328.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):257-62 [9683303.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1715-20 [2306725.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1068-74 [9508192.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Cancer Res. 1989 Aug 1;49(15):4098-102 [2472873.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2785-90 [8874340.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1316-20 [7882329.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2114-22 [11304763.001]
  • [Cites] Cancer Treat Rev. 1994 Jan;20(1):73-96 [8293429.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 17;85(4):271-91 [8381186.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] Jpn J Cancer Res. 1999 Oct;90(10):1163-70 [10595746.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10 ):3329-34 [9779709.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4187-91 [1651156.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4271-5 [10485471.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):210-21 [7799022.001]
  • [Cites] Br J Cancer. 1996 Mar;73(6):744-50 [8611374.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 19;83(12):855-61 [1648142.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):207-10 [10761757.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):265-71 [9920950.001]
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):595-604 [9533526.001]
  • [Cites] Am J Med. 1979 Apr;66(4):625-30 [219690.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 17;84(12 ):972-4 [1321253.001]
  • [Cites] Jpn J Cancer Res. 1989 Jan;80(1):69-76 [2496061.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2345-52 [8708727.001]
  • [Cites] Br J Cancer. 1996 Aug;74(3):327-38 [8695345.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2090-6 [9164222.001]
  • [Cites] Int J Cancer. 1992 Mar 12;50(5):760-6 [1312063.001]
  • (PMID = 11177750.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase I Inhibitors; 0H43101T0J / irinotecan; EC 5.99.1.2 / DNA Topoisomerases, Type I; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 50
  •  go-up   go-down


11. Segawa Y, Ueoka H, Kiura K, Tabata M, Takigawa N, Hiraki Y, Watanabe Y, Yonei T, Moritaka T, Hiyama J, Hiraki S, Tanimoto M, Harada M, Okayama Lung Cancer Study Group: Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. Lung Cancer; 2003 Jul;41(1):13-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer.
  • To improve the efficacy of a combination of cisplatin and etoposide and concurrent accelerated twice-daily thoracic radiotherapy against limited-stage small-cell lung cancer, we conducted a phase I/II study using an altered schedule of chemotherapy administration.
  • Chemotherapy consisted of four cycles of cisplatin (days 1 and 8) and etoposide (days 1, 2, 8, and 9) every 4 weeks.
  • Accelerated hyperfractionated thoracic radiation (1.5 Gy twice daily x 30 fractions, total dose of 45 Gy) was concurrently given with the first cycle of chemotherapy.
  • By a median follow-up time of 29 months, median radiation-outfield progression-free survival was 13.4 months, while radiation-infield progression-free survival did not reach median value.
  • The median overall survival time was 22.9 months, with survival rate of 48.4% at 2 years.
  • However, the insufficient distant control suggests a need for development of more active chemotherapy regimens.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Cisplatin / administration & dosage. Etoposide / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cohort Studies. Combined Modality Therapy. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12826307.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, Souquet PJ, Court-Fortune I, Trillet-Lenoir V, Fournel C, Tod M, Freyer G: Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer; 2008 Nov;62(2):261-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
  • PURPOSE: To investigate the prognostic value of systemic exposure to etoposide (Area Under the concentration Curve (AUC(VP16))) on overall survival (OS) in patients with small cell lung cancer (SCLC).
  • PATIENTS AND METHODS: Data from 52 patients with limited stage (n=17) or metastatic (n=35) SCLC were analysed.
  • RESULTS: Etoposide plasma concentration vs. time was described by a two compartment model.
  • Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).
  • Median percent decrease of absolute neutrophil count (ANC) after the first chemotherapy course was greater when etoposide 24h concentration was above 0.33mg/L (88% vs. 0%, p=0.028).
  • Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).
  • CL(VP16) and AUC(VP16) correlate significantly with overall survival of patients with SCLC patients receiving etoposide regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Etoposide / administration & dosage. Etoposide / pharmacokinetics. Lung Neoplasms / drug therapy. Small Cell Lung Carcinoma / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18442869.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V, Greek Lung Cancer Cooperative Group: A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol; 2001 Apr;12(4):463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
  • BACKGROUND: Previous phase I-II studies have shown that the combination of paclitaxel-cisplatin-etoposide (TEP) is very active and well tolerated in patients with small-cell lung cancer (SCLC).
  • In order to compare the TEP combination to cisplatin etoposide (EP) regimen as front-line treatment in patients with SCLC, we conducted a randomised multicenter study.
  • PATIENTS AND METHODS: One hundred thirty-three chemotherapy-naïve patients with histologically proven limited or extensive stage SCLC were randomised to receive either paclitaxel 175 mg/m2 i.v. three-hour infusion on day 1 and cisplatin 80 mg/m2 i.v. on day 2 and etoposide 80 mg/m2 i.v. on days 2-4 with G-CSF support (5 mcg/kg s.c. days 5-15) or cisplatin 80 mg/m2 i.v. on day 1 and etoposide 120 mg/m2 i.v. on days 1-3 in cycles every twenty-eight days.
  • Sixty-two patients received two hundred sixty-one cycles of TEP and seventy-one patients three hundred twenty-three cycles of EP The two patient groups were well balanced for age, sex, performance status, stage of disease and the presence of abnormal LDH at diagnosis.
  • In an intention-to-treat overall analysis both regimens were equally active with a complete and partial response rate of 50% (95% confidence interval (CI): 37.5%-62.4%) for TEP and 48% (95%) CI: 36.2%-59.5%) for EP (P = 0.8).
  • The median time to disease progression was 11 months for TEP and 9 months for EP (P = 0.02).
  • Similarly, in an intention-to-treat subgroup analysis of patients with limited or extensive stage disease, there was no difference in the activity between the two regimens except of a longer median time to disease progression in the extensive stage in favour of the TEP regimen, eight versus six months (P = 0.04).
  • The TEP regimen is associated with significant toxicity and mortality, and should not be used outside of a protocol setting.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11398877.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Blackstock AW, Bogart JA, Matthews C, Lovato JF, McCoy T, Livengood K, Ho C, White D, Atkins JN, Miller AA: Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial. Clin Lung Cancer; 2005 Mar;6(5):287-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
  • The optimal integration of radiation and chemotherapy for limited-stage small-cell lung cancer (SCLC) remains unclear.
  • This phase III trial was conducted to determine whether chemotherapy plus interdigitating split-course thoracic radiation therapy (RT) improved survival compared with standard-dose continuous thoracic RT.
  • One hundred fourteen patients were randomized to receive 50 Gy thoracic RT delivered in 2.0-Gy fractions given continuously (5 weeks) concurrent with the first 2 cycles of chemotherapy (arm A) or 50 Gy delivered via an interdigitating split course in 2.5-Gy fractions (8 weeks) concurrent with the first 3 cycles of chemotherapy (arm B).
  • All patients received the following chemotherapy: cisplatin/etoposide on cycles 1, 2, and 5 and cyclophosphamide/vincristine/doxorubicin on cycles 3, 4, and 6.
  • Prophylactic cranial irradiation was recommended after a complete response to all therapy.
  • Grade 3/4 hematologic toxicity was common in both treatment arms.
  • Interdigitating split-course thoracic RT delivered in 2.5-Gy fractions was tolerable in patients with limited-stage SCLC but did not provide a survival advantage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose Fractionation. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Survival Analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15845179.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S: Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial. Int J Radiat Oncol Biol Phys; 2005 Jan 1;61(1):70-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
  • PURPOSE: To fit the situation of developing countries, where supportive care is not sufficient, a modified combined therapy of cisplatin/etoposide (EP) and hyperfractionated accelerated radiation therapy (HART) was conducted as a Phase II trial for limited-stage small-cell lung cancer (LSCLC) to evaluate the feasibility, toxicity, and tolerance of the combined therapy and to observe its efficacy and patterns of failure.
  • METHODS AND MATERIALS: Chemotherapy and radiation were sequentially administered in 1 to 3 cycles before and 3 to 5 cycles after HART.
  • Chemotherapy contained cisplatin in doses of 25 to 30 mg/m(2) from Day 1 to Day 3 and etoposide in doses of 50 to 70 mg/m(2) from Day 1 to Day 3.
  • The HART schedule consisted of radiation delivered in 1.4-Gy fractions, twice a day, at intervals longer than 6 h for 5 treatment days a week, to a total dose of 56 Gy in 40 fractions over 4 weeks.
  • All were limited stage, and the median age was 60 years (range, 25 to 70 years).
  • Fifty-four patients completed the planned combined treatment.
  • A median of 6 cycles of chemotherapy (range, 5-8 cycles) was administered during a median interval of 4.9 weeks (range, 3.0-8.9 weeks), and a radiation dose of 56 Gy in 40 fractions was delivered over 29 days.
  • The median survival time was 24 months (95% CI, 21-28 months).
  • (1) LSCLC patients tolerate HART at 56 Gy in 40 fractions over 4 weeks combined with 6 cycles of EP chemotherapy. (2) Both control of the tumor in the thorax and survival appear superior to conventional fractionated radiation but not as good as that in a study by Turrisi and colleagues. (3) This modified chemoradiation schedule could be recommended to LSCLC patients in developing countries. (4) The lessons learned from our study are (a) higher radiation doses may be needed for better locoregional control, and (b) prophylactic cranial irradiation is necessary for LSCLC patients who show complete response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Etoposide / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15629596.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Quoix E, Purohit A, Faller-Beau M, Moreau L, Oster JP, Pauli G: Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer; 2000 Nov;30(2):127-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy.
  • The influence of pretreatment serum levels of lactate dehydrogenase (LDH) and neuron-specific enolase (NSE) on survival was investigated in a series of 263 consecutive patients with small-cell lung cancer.
  • Both were significantly higher when the disease was considered extensive than when it was limited.
  • The multivariate survival analysis of the entire population showed that LDH, along with performance status, extent of disease, and albumin, was a more important prognostic factor than NSE.
  • In the separate multivariate survival analyses of limited and extensive disease, LDH remained an independent prognostic factor.
  • For extensive disease, NSE did not even appear in the model when LDH was excluded; for limited stage disease, NSE did become a weak independent prognostic factor when LDH was excluded.
  • In conclusion, LDH, which is less expensive to assay than NSE, is also a stronger independent prognostic factor for small-cell lung cancer and should be part of the initial work-up.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Small Cell / diagnosis. L-Lactate Dehydrogenase / metabolism. Lung Neoplasms / diagnosis. Phosphopyruvate Hydratase / metabolism. Platinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2000 Oct;30(1):51-3 [11008009.001]
  • (PMID = 11086206.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platinum Compounds; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


17. Wen YK, Chen ML: Acute renal failure secondary to small cell lung cancer with tumor infiltration of the kidneys. Ren Fail; 2006;28(3):261-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure secondary to small cell lung cancer with tumor infiltration of the kidneys.
  • We report a 64-year-old man previously diagnosed with limited stage small cell lung cancer who presented with acute renal failure (ARF).
  • A kidney biopsy established the diagnosis of metastatic small cell lung cancer with diffuse renal parenchymal infiltration.
  • This case emphasizes the rare potential for cancers to metastasize to the kidneys, which can result in ARF.
  • Early recognition of this cause of ARF is crucial, in particular, when the tumor is amenable to chemotherapy or irradiation.
  • [MeSH-major] Acute Kidney Injury / etiology. Carcinoma, Small Cell / secondary. Kidney Neoplasms / complications. Kidney Neoplasms / secondary. Lung Neoplasms / pathology


18. Wang S, Bruzzi J, Rodriguez-Garza VP, Komaki RR: Lambert-eaton myasthenic syndrome in a patient with small-cell lung cancer. Clin Lung Cancer; 2006 Jan;7(4):282-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lambert-eaton myasthenic syndrome in a patient with small-cell lung cancer.
  • Lambert-Eaton myasthenic syndrome (LEMS), an autoimmune neuromuscular disorder, often has underlying small-cell lung cancer (SCLC).
  • Thorough search for SCLC in patients with LEMS can result in early detection of limited-stage SCLC, one quarter of which can be successfully treated with chemotherapy and radiation therapy.
  • To elucidate the pathogenesis, diagnosis, treatment, and prognosis of patients with SCLC and LEMS, we present a 51-year-old man who was diagnosed with LEMS and limited-stage SCLC after an 18-month history of weakness in the lower extremities.
  • The patient exhibited a complete response in lung tumors and a resolution in LEMS symptoms after chemotherapy and radiation therapy.
  • [MeSH-major] Carcinoma, Small Cell / complications. Lambert-Eaton Myasthenic Syndrome / complications. Lung Neoplasms / complications


19. Videtic GM, Truong PT, Dar AR, Yu EW, Stitt LW: Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Int J Radiat Oncol Biol Phys; 2003 Nov 1;57(3):709-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
  • PURPOSE: To perform a retrospective review of a single institution's 10-year experience in treating limited-stage small-cell lung cancer (LS-SCLC) with a concurrent chemoradiation regimen modeled after the experimental arm of a randomized National Cancer Institute of Canada trial in which hypofractionated radiotherapy started with cycle 2 of chemotherapy.
  • We then looked at the impact on patient outcomes of changing the RT during the course of the decade to a "conventionally" (2 Gy) fractionated regimen, with a focus on toxicity and survival rates.
  • METHODS AND MATERIALS: Between 1989 and 1999, 215 LS-SCLC patients received six cycles of chemotherapy consisting of cyclophosphamide, doxorubicin, and vincristine alternating with etoposide and cisplatin every 3 weeks.
  • Thoracic RT was administered concurrently with etoposide and cisplatin (at cycle 2 or 3) only and consisted of either 40 Gy in 15 fractions for 3 weeks or 50 Gy in 25 fractions for 5 weeks.
  • RT fields encompassed gross and suspected microscopic disease with 2-cm margins.
  • RT interruption during concurrent chemoradiation was used as the "marker" for treatment toxicity.
  • RESULTS: The overall survival rate for 215 patients at 2 and 5 years was 22.7% and 7.2%, respectively, with a median survival of 14.7 months.
  • Thoracic RT consisted of 40 Gy in 3 weeks for 122 patients (57%) and 50 Gy in 5 weeks for 92 patients (43%).
  • PCI was administered to 21 (44%) and 47 (56%) patients receiving 40 Gy and 50 Gy, respectively.
  • The patient- and treatment-related variables were comparable between the two cohorts treated with the different RT prescriptions.
  • RT interruptions during concurrent chemoradiation were recorded in 56 cases (26%), with a median duration of 5 days (range 1-18).
  • No differences in treatment-related toxicity rates were demonstrated between the two dose cohorts (p = 0.35).
  • The overall and disease-free survival rates (patients stratified by PCI use) at 5 years for the 40- and 50-Gy schedules were 14.3% and 12.0% (p = 0.71) and 20.7% and 22.2% (p = 0.76), respectively.
  • Comparing the 40-Gy and 50-Gy cohorts, the rate of any first relapse was 40% vs. 42% and the chest as the first relapse site was 34% vs. 45% (patients stratified by PCI use), respectively.
  • In view of the benefits that accelerated schedules provide for both patients and cost containment, clinicians may opt to use this tolerable regimen in managing LS-SCLC.
  • Regarding the future development of novel chemoradiation programs, the most critical factor in ensuring improved outcomes for LS-SCLC may be limiting the duration of RT and overall treatment time.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14529775.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Sher T, Dy GK, Adjei AA: Small cell lung cancer. Mayo Clin Proc; 2008 Mar;83(3):355-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell lung cancer.
  • Small cell lung cancer accounts for approximately 15% of bronchogenic carcinomas.
  • It is the cancer most commonly associated with various paraneoplastic syndromes, including the syndrome of inappropriate antidiuretic hormone secretion, paraneoplastic cerebellar degeneration, and Lambert-Eaton myasthenic syndrome.
  • Because of the high propensity of small cell lung cancer to metastasize early, surgery has a limited role as primary therapy.
  • Although the disease is highly sensitive to chemotherapy and radiation, cure is difficult to achieve.
  • It is also the accepted standard therapy in combination with thoracic radiotherapy (TRT) for limited-stage disease.
  • Adding TRT increases absolute survival by approximately 5% over chemotherapy alone.
  • Thoracic radiotherapy administered concurrently with chemotherapy is more efficacious than sequential therapy.
  • Furthermore, the survival benefit is greater if TRT is given early rather than late in the course of chemotherapy.
  • Regardless of disease stage, no relevant survival benefit results from increased chemotherapy dose intensity or dose density, altered mode of administration (eg, alternating or sequential administration) of various chemotherapeutic agents, or maintenance chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell. Lung Neoplasms
  • [MeSH-minor] Combined Modality Therapy / methods. Diagnosis, Differential. Humans. Morbidity. Prognosis. Survival Rate. United States / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316005.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 133
  •  go-up   go-down


21. Neninger E, Díaz RM, de la Torre A, Rives R, Díaz A, Saurez G, Gabri MR, Alonso DF, Wilkinson B, Alfonso AM, Combet T, Pérez R, Vázquez AM: Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther; 2007 Feb;6(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.
  • We conducted a Phase I clinical trial to evaluate the toxicity and humoral immune response elicited by 1E10 vaccine in patients with small cell lung cancer (SCLC).
  • Eligible patients were those who after received chemotherapy and/or radiotherapy had partial or complete response to treatment.
  • Six patients with limited-stage disease and three with extensive-stage disease were enrolled in the study.
  • Most of the patients who received at least four doses of 1E10 vaccine developed strong specific antibody responses against 1E10 MAb and NeuGc-GM3 ganglioside.
  • Antibodies able to react with lung carcinoma tissue sections were detected in sera from vaccinated patients.
  • [MeSH-major] Antibodies, Anti-Idiotypic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Animals. Antibody Specificity. Binding Sites, Antibody. Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Female. G(M3) Ganglioside / immunology. Humans. Immunohistochemistry. Immunotherapy, Active. Male. Mice. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2007 Feb;6(2):151-2 [17426436.001]
  • (PMID = 17218777.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / G(M3) Ganglioside
  •  go-up   go-down


22. Bagan P, Berna P, Brian E, Crockett F, Le Pimpec-Barthes F, Dujon A, Riquet M: Induction chemotherapy before sleeve lobectomy for lung cancer: immediate and long-term results. Ann Thorac Surg; 2009 Dec;88(6):1732-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy before sleeve lobectomy for lung cancer: immediate and long-term results.
  • BACKGROUND: Induction chemotherapy does not increase the morbidity and mortality rates of bronchoplastic procedures, but the long-term efficiency remains unclear.
  • The purpose of this retrospective study was to analyze the impact of chemotherapy on resectability and long-term survival.
  • METHODS: From 1984 to 2005, 159 consecutive patients with non-small cell lung cancer underwent sleeve lobectomy without (n = 117) or with induction chemotherapy (n = 42).
  • Indications for chemotherapy were N2 lymph node involvement (n = 15), T3 or T4 tumor invasion with doubtful resectability (n = 13), need for tumor size reduction (n = 8), lung function precluding pneumonectomy (n = 4), and brain metastasis (n = 2).
  • None of the patients received induction radiation therapy.
  • RESULTS: Clinical stage III was predominant in the induction chemotherapy group whereas stage II was predominant in the surgery-only group.
  • Complication rates in the induction chemotherapy group and in the surgery-only group were 23.8% and 24.7%, respectively.
  • We observed a greater rate of 1-month-delay smoking cessation before surgery in the induction chemotherapy group (40% versus 22%).
  • The 5-year survival rates were 65.4% in the surgery-only group and 73.4% in the induction chemotherapy group (p = 0.5).
  • The tumor size in the induction chemotherapy group was lower (17.5 versus 30.6 mm; p = 0.01), which reflected the positive impact of chemotherapy on sleeve resection feasibility.
  • CONCLUSIONS: Induction chemotherapy before sleeve lobectomy achieves good long-term results.
  • Tumor reduction and limited resection feasibility seemed to be increased, which justify further prospective trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Pneumonectomy / methods. Preoperative Care / methods
  • [MeSH-minor] Bronchoscopy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2009 Dec;88(6):1736 [19932226.001]
  • (PMID = 19932225.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Westphal FL, Lima LC, Andrade EO, Lima Netto JC, Silva AS, Carvalho BC: Characteristics of patients with lung cancer in the city of Manaus, Brazil. J Bras Pneumol; 2009 Feb;35(2):157-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with lung cancer in the city of Manaus, Brazil.
  • OBJECTIVE: To analyze the characteristics of patients with lung cancer.
  • METHODS: A retrospective descriptive study of patients receiving a histopathological diagnosis of lung cancer between 1995 and 2002 in the city of Manaus, Brazil.
  • The following histological types were identified: squamous cell carcinoma, 62.8%; adenocarcinoma, 24.7%; small cell carcinoma, 9.1%; and large cell carcinoma, 3.4%.
  • Of the total sample, 73.4% were submitted to treatment.
  • Of these, 51.4% underwent radiotherapy; 16.6%, surgery; 15.8%, chemotherapy; and 16.2%, radiotherapy in association with chemotherapy.
  • CONCLUSIONS: In this group of patients with lung cancer, survival rates were considerably lower than those reported in the literature.
  • This might be attributable to the limited access to the specialized health care system and the advanced stage of the disease at diagnosis.
  • [MeSH-major] Carcinoma, Large Cell / mortality. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality. Small Cell Lung Carcinoma / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Brazil / epidemiology. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sex Factors. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287919.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Brazil
  •  go-up   go-down


24. Yue X, Zang QC: [Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases]. Ai Zheng; 2004 Dec;23(12):1671-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases].
  • BACKGROUND & OBJECTIVE: Median survival time (MST) of small cell lung cancer (SCLC) patients with brain metastases was short when patients were palliatively treated with either chemotherapy or whole brain radiotherapy (WBRT).
  • This study was designed to compare therapeutic effects,toxicities,and survival time of 2 different sequential treatments of VmP regimen and WBRT for SCLC patients with brain metastases.
  • METHODS: According to bed availability, 38 naive SCLC patients with brain metastases were nonrandomized into group A and group B.
  • Patients in group A (VmP-WBRT) received 2 cycles of VmP regimen (teniposide, 60 mg/m(2),d(1-5), cisplatin, 25 mg/m(2), d(1-3), repeated every 4 weeks),and then WBRT (3 Gy x 10,within 2 weeks); patients in group B (WBRT-VmP) received the same WBRT in advance,and then 2 cycles of VmP regimen.
  • Patients with single brain lesion received an extra 3 Gy x 5 radiotherapy on the limited field of brain lesion within 1 week after WBRT.
  • All patients received 2-4 cycles of chemotherapy after sequential treatments.
  • RESULTS: Both sequential treatments relieved neurological symptoms of more than 80% of patients.
  • Response rates of brain,lung,and total lesions of group A and B had no significant differences (68.2% vs. 75.0%, P=0.647; 77.3% vs. 75%, P=0.871; 63.6% vs. 56.3%, P=0.646,respectively).
  • Time to progression (TTP) of group A was 6.0 (95% CI 4.4-7.6) months,of group B was 5.0 (95% CI 3.6-6.4) months (P=0.383).
  • Incidence of vomit at stage III in group B was higher than that in group A (P=0.01).
  • All treatment toxicities were tolerable and manageable.
  • CONCLUSION: Both sequential treatments can be safely performed for SCLC patients with brain metastases, may relieve neurological symptoms, and well control both primary and metastatic lesions.
  • VmP-WBRT sequential treatment may prolong survival time of SCLC patients for 3 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Carcinoma, Small Cell / therapy. Cranial Irradiation. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Leukopenia / etiology. Male. Middle Aged. Prospective Studies. Survival Rate. Teniposide / administration & dosage


25. J Barata F, Costa AF: [Small cell lung cancer--state of the art and future perspectives]. Rev Port Pneumol; 2007 Jul-Aug;13(4):587-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell lung cancer--state of the art and future perspectives].
  • [Transliterated title] Carcinoma do pulmão de pequenas células--Estado da arte e perspectivas futuras.
  • Lung cancer is the leading cause of cancer-related death in Portugal.
  • Almost 3500 Portuguese are expected to be diagnosed with lung cancer in 2006; approximately 20% will have small cell lung cancer (SCLC).
  • At presentation, 25% to 30% of patients will have local or regional disease, classified as limited stage disease.
  • The concurrent chemovalidation therapy is the best choice.
  • Once daily thoracic radiation therapy to doses in the range of 50 Gy to 60 Gy would reflect an accepted standard of care in daily practice.
  • Because of the increase toxicity associated with hyper fractionated radiation, this approach is often limited to select patients.
  • This is the standard regimen for concomitant therapy in limited stage and for extensive disease SCLC.
  • Despite good chemo sensitivity and radio sensitivity, the prognosis of SCLC is very poor because of the early development of resistance and the associated high tendency to recurrence, making second line treatment of SCLC a problem of real medical relevance.
  • Topotecan now offers an effective and well tolerated monosubstance for second line therapy of recurrent SCLC.
  • There has been a significant increase in median survival for patients with SCLC receiving topotecan plus symptomatic therapy versus symptomatic therapy.
  • The efficacy of this drug is comparable to the efficacy of the three-drug combination CAV.
  • The combination of topotecan with cranial radiotherapy is well tolerated and effective in the treatment of cerebral metastases of SCLC.
  • New classes of agents, such as antiangiogenic agents including bevacizumab, small molecule tyrosine kinase inhibitors and thalidomide are being evaluated with chemotherapy for patients with extensive stage SCLC.
  • [MeSH-major] Carcinoma, Small Cell. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898914.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 78
  •  go-up   go-down


26. Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR: Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol; 2006 Nov;1(9):996-1001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
  • BACKGROUND: In preclinical models, the proteasome inhibitor bortezomib (PS-341) inhibits the growth of small cell lung cancer (SCLC) by inhibiting the antiapoptotic Bcl-2 signaling pathway.
  • We conducted a phase II trial of PS-341 in previously treated patients with platinum-sensitive and -refractory extensive stage SCLC to determine response rate, toxicity, and survival.
  • METHODS: Patients with histologically confirmed SCLC, measurable disease, Zubrod performance status 0-1, and previous treatment with platinum-based therapy were enrolled.
  • They were stratified by platinum-sensitivity status: sensitive (relapse >90 days after platinum) or refractory (progression during or < or =90 days after platinum).
  • Twenty-nine patients (52%) had received two or more previous chemotherapy regimens.
  • Ten patients (18%) discontinued treatment due to adverse events or side effects.
  • CONCLUSION: Although PS-341 induced a response in a patient with platinum-refractory disease, it has limited single-agent activity in this heavily pretreated cohort.
  • As shown in preclinical models, testing of PS-341 in combination with an apoptotic trigger such as chemotherapy, is a rational clinical approach.
  • [MeSH-major] Boronic Acids / administration & dosage. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrazines / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bortezomib. Confidence Intervals. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Infusions, Intravenous. Maximum Tolerated Dose. Middle Aged. Probability. Remission Induction. Risk Assessment. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409985.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA105409; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46136; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / CA76447
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


27. Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ: Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol; 2005 Nov 20;23(33):8371-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
  • PURPOSE: Ifosfamide, carboplatin, etoposide, and vincristine, alone and in combination, are highly active against small-cell lung cancer (SCLC).
  • This trial was designed to investigate whether survival could be improved by a regimen of all four drugs (ICE-V) compared with standard chemotherapy in patients with SCLC and good performance status, and to assess the patients' quality of life (QL).
  • PATIENTS AND METHODS: Patients were randomly assigned to receive six cycles of either ICE-V at 4-week intervals without dose reduction or standard chemotherapy administered according to local practice.
  • There was no evidence that the relative survival benefit for ICE-V was less in extensive-stage than in limited-stage patients.
  • An increased rate of septicemia was reported in the ICE-V group (15% v 7% in the control group), but this did not result in an increase in reported treatment-related deaths (four patients [2%] in both groups).
  • CONCLUSION: Compared with standard chemotherapy, the ICE-V regimen improves overall survival without QL penalties, despite an increased but manageable level of toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2006 Jul;3(7):360-1 [16826215.001]
  • (PMID = 16293867.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


28. Greco FA: Topotecan as first-line therapy for small cell lung cancer. Lung Cancer; 2003 Aug;41 Suppl 4:S9-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan as first-line therapy for small cell lung cancer.
  • Although current treatments for small-cell lung cancer (SCLC) yield objective response rates exceeding 50%, most patients relapse.
  • Hence, research into the identification of novel agents and combinations that may improve therapy is ongoing.
  • Topotecan, an established treatment for patients with recurrent SCLC, is being investigated as first-line therapy for SCLC because of its novel mechanism of action, non-cumulative toxicity and in vitro synergy with other active agents.
  • Several phase II studies of doublet and triplet combination therapy with other agents, including paclitaxel, cisplatin, carboplatin and etoposide, have reported promising results for first-line treatment of SCLC.
  • For example, in combination with paclitaxel, complete and overall responses were 3-67% and 45-100%, respectively, in extensive-stage disease.
  • Furthermore, two studies of the triplet combination of topotecan with paclitaxel plus carboplatin yielded impressive complete response rates of 37-51% in limited-stage SCLC.
  • The most frequent adverse events associated with topotecan-based regimens have been reported as neutropenia and thrombocytopenia so growth factor support is often incorporated into treatments.
  • Several ongoing phase III studies will help to clarify the role of topotecan in the first-line treatment of SCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Topotecan / therapeutic use
  • [MeSH-minor] Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Forecasting. Humans. Paclitaxel / administration & dosage. Platinum / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565509.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 49DFR088MY / Platinum; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Georgoulias V, Scagliotti G, Miller V, Eckardt J, Douillard JY, Manegold C: Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. Semin Oncol; 2001 Feb;28 Suppl 2:15-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
  • The limited single-agent activity of cisplatin, its toxicity profile, and the inconvenience involved in hydrating patients has compelled researchers to investigate other treatments as possible alternative therapies in non-small cell lung cancer.
  • Phase II studies show that the combination of docetaxel (Taxotere; Aventis, Antony, France) and gemcitabine is active in stage IIIB/IV non-small cell lung cancer not previously treated by chemotherapy.
  • Response rates of up to 54% and a median survival time of 13 months have been reported.
  • The combination of docetaxel plus vinorelbine is also active in non-small cell lung cancer and preliminary data suggest that this schedule with prophylactic filgrastim may optimize tolerability and dose intensity.
  • Docetaxel combined with other new agents, particularly gemcitabine, may offer another useful alternative to cisplatin-based chemotherapy in patients with good performance status.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140077.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Poortmans PM, Richaud P, Collette L, Ho Goey S, Pierart M, Van Der Hulst M, Bolla M, EORTC Radiation Oncology Group: Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder. Acta Oncol; 2008;47(5):937-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
  • INTRODUCTION: We prospectively evaluated concomitant radiotherapy and chemotherapy for advanced bladder cancer in a phase II EORTC trial to test whether it could be further studied as a potential treatment of bladder cancer.
  • PATIENTS AND METHODS: Patients up to 75 years of age with invasive transitional-cell carcinoma of the bladder up to 5 cm, stage pT2 to pT3b, N0M0, without residual macroscopical tumour after transurethral excision were eligible.
  • Radiotherapy consisted of 2 fractions of 1.2 Gy daily up to 60 Gy delivered in a period of 5 weeks.
  • Five patients had tumour stage pT2, 1 stage pT3a and 3 stage pT3b.
  • All patients completed radiotherapy and chemotherapy as scheduled.
  • All patients were evaluated 3 months after treatment: eight patients had no detectable tumour and one had para-aortic lymph nodes.
  • During further follow-up, a second patient got lymph node metastases and two patients developed distant metastases (lung in the patient with enlarged lymph nodes at the first evaluation and abdominal in one other).
  • Late toxicity was limited and often temporary.
  • Six patients remained alive without disease.
  • DISCUSSION: Despite the small cohort, this combination of concomitant chemotherapy and accelerated hyperfractionated radiotherapy for invasive bladder cancer seemed to be well tolerated and to result in satisfactory local control with limited early and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / radiotherapy. Prospective Studies. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568488.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-27; United States / NCI NIH HHS / CA / 5U10 CA11488-37
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Agelaki S, Syrigos K, Christophylakis C, Boukovinas J, Varthalitis J, Pavlakou G, Athanasiadis A, Kouroussis C, Vardakis N, Maltezakis G, Milaki G, Georgoulias V, Lung Cancer Subgroup, Hellenic Oncology Research Group: A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology; 2004;66(3):192-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
  • OBJECTIVE: To evaluate efficacy and toxicity of the combination of irinotecan and gemcitabine in pretreated patients having small-cell lung cancer.
  • PATIENTS AND METHODS: Thirty-one patients (median age 60 years, performance status 0-1 in 87% and 2 in 13% of the patients) with limited or extensive-stage disease, refractory or relapsing after at least one prior chemotherapy regimen, received gemcitabine 1,000 mg/m(2) on days 1 and 8 and irinotecan 300 mg/m(2) on day 8, every 21 days.
  • Sixteen (52%) patients had sensitive and 15 (48%) refractory disease.
  • Three partial responses were documented for an overall response rate of 10% (95% CI 0.73-20.09), and disease stabilization was obtained in 7 patients (22%; intention-to-treat analysis).
  • Two of the responders had refractory, and 1 had sensitive disease.
  • The median time to progression was 4.5 months, the median duration of responses was 2.5 months, and the median survival time was 6 months.
  • CONCLUSIONS: The combination showed modest activity in this patient group with a poor prognosis.
  • Thus we believe it merits further investigation in the treatment of patients with small-cell lung cancer who have failed one prior chemotherapy regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Small Cell / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15218309.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


32. Sörenson S, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol; 2001;40(2-3):327-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic overview of chemotherapy effects in non-small cell lung cancer.
  • A systematic review of chemotherapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU).
  • This overview of the literature on chemotherapy for non-small cell lung cancer (NSCLC) is based on 53 scientific publications including six meta-analyses based on 65 prospective randomised trials comprising 15,607 patients and an additional 32 prospective randomised studies including 8,902 patients.
  • The conclusions reached can be summarised into the following points: In stage IIIB-IV disease, published data demonstrate that cisplatin-based chemotherapy confers a modest, median 1.5-3 months, prolongation of survival.
  • Randomised studies indicate symptomatic relief and improvement of indices of quality of life (QoL) for patients who receive platinum-based combination chemotherapy or single drug therapy with more recent compounds.
  • Data supporting the use of chemotherapy are not available for patients in poor general condition (WHO performance status 3 4) and evidence is limited for elderly patients (above 70-75 years).
  • Platinum-based chemotherapy can be recommended for selective use in routine care of advanced NSCLC although patients should be encouraged to participate in controlled clinical trials to further elucidate the role of chemotherapy in advanced disease.
  • In advanced disease, recent data suggest that the newer agents gemcitabine, paclitaxel, irinotecan and vinorelbine, in combination with cisplatin, provide an additional survival benefit compared with earlier cisplatin-based regimens.
  • A standard regimen for advanced disease cannot yet be defined.
  • At progression after platinum-based chemotherapy for advanced disease, limited data indicate a small survival benefit from docetaxel over supportive care alone.
  • Such second-line chemotherapy of advanced disease can be recommended for selected patients but should preferably be confined to controlled clinical trials.
  • In stage III disease, published data show that induction cisplatin-based chemotherapy before radical radiotherapy modestly prolongs long-term survival and lowers the incidence of distant metastases compared with radiotherapy alone.
  • Chemotherapy in this setting can be recommended for selected patients but treatment should preferably be given within a controlled clinical trial.
  • In stage IIIAN2 disease, data from pilot studies demonstrate that surgery after induction chemotherapy is feasible.
  • Two small randomised studies demonstrate a significant survival advantage for induction chemotherapy followed by surgery compared with surgery alone.
  • Induction chemotherapy can be recommended for selected patients but treatment should preferably be given within a controlled clinical trial.
  • The superiority of induction chemotherapy plus surgery compared with combined chemotherapy and radical irradiation has not been proven in a randomised trial but currently such studies are under way.
  • In the adjuvant setting, published data suggest that cisplatin-based chemotherapy after radical surgery may increase five-year survival from around 50% by a further 5% but the confidence interval for this estimate is too wide for firm conclusions.
  • Large-scale prospective randomised trials are under way to resolve this important issue and adjuvant chemotherapy is, thus, not recommended for routine treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Neoplasm Staging. Prognosis. Survival Analysis


33. Gressen EL, Curran WJ: Hyperfractionated radiotherapy for lung cancer. Curr Oncol Rep; 2000 Jan;2(1):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiotherapy for lung cancer.
  • In several recent clinical trials, hyperfractionated or accelerated hyperfractionated thoracic radiation therapy has improved survival over conventional radiotherapy among patients with either stage III non-small-cell lung cancer or limited-stage small-cell lung cancer.
  • Combinations of novel chemotherapy agents such as taxanes and gemcitabine with hyperfractionated or accelerated hyperfractionated radiotherapy may further improve survival, although toxicity must be closely followed.
  • Attempts to minimize the amount of normal tissue radiated through either three-dimensional treatment planning or use of a radioprotector (such as amifostine) may allow therapeutic escalation with chemoradiation and further success at treating the number one cause of cancer-related mortality in the United States.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Dose Fractionation. Humans. Neoplasm Staging. Radiation-Protective Agents / therapeutic use. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1563-74 [2167954.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):537-44 [9336129.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):487-94 [9806505.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):452-8 [7844608.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):198-205 [7707407.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1037-48 [9506347.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1091-6 [9869234.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1323-8 [9823973.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):893-900 [9060525.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):265-71 [9920950.001]
  • [Cites] Lancet. 1997 Jul 19;350(9072):161-5 [9250182.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5 [8780630.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469-78 [9806503.001]
  • (PMID = 11122827.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Protective Agents
  • [Number-of-references] 16
  •  go-up   go-down


34. Puma F, Urbani M, Santoprete S, Ricci F, Sanguinetti A, Vinci D, Ottavi P, Porcaro G, Daddi G: [The role of surgery in the treatment of small cell lung cancer]. Minerva Endocrinol; 2001 Dec;26(4):247-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of surgery in the treatment of small cell lung cancer].
  • [Transliterated title] Ruolo della chirurgia nel trattamento del microcitoma polmonare.
  • Small cell lung cancer (SCLC) is a biologically aggressive tumor with a low long-term survival rate.
  • SCLC is highly responsive to chemotherapy and surgery has a very limited role in its treatment because the disease is usually widely disseminated at the diagnosis.
  • Good results from surgery have been reported in the small subgroup of T1-2 N0 M0 patients.
  • In N1 peripheral SCLC, surgery in combination with other treatments, can obtain fair results.
  • Surgical treatment does not influence the prognosis in SCLC as stage III and IV.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11782710.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Braybrooke JP, Ranson M, Manegold C, Mattson K, Thatcher N, Cheverton P, Sekiguchi M, Suzuki M, Oyama R, Talbot DC: Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer; 2003 Aug;41(2):215-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
  • This multi-centre phase II study evaluated the activity of single agent exatecan in previously untreated patients with advanced non-small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Patients with histologically or cytologically proven stage IIIb or IV NSCLC were treated with exatecan 0.5 mg/m(2) per day by 30 min intra-venous (i.v.) infusion for 5 days every 3 weeks to a maximum of six cycles.
  • Measurable disease was documented prior to study entry and patients were re-staged every two cycles.
  • 0.3-21.3%) had a partial response, 7 (18.0%) minor response and 8 (20.5%) stable disease.
  • Median time to tumour progression (TTP) was 88 days and median overall survival 262 days.
  • CONCLUSIONS: Exatecan mesylate has limited activity in advanced NSCLC and is not recommended for further evaluation as a single agent in this tumour type.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Finland. Germany. Great Britain. Humans. Infusions, Intravenous. Japan. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Treatment Outcome


36. Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A, Han P, Choi K, Rotman M: Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer; 2010 Mar 1;116(5):1350-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?
  • BACKGROUND: Although chemotherapy and radiation therapy currently are recommended in limited-stage small cell lung cancer (L-SCLC), several small series have reported favorable survival outcomes in patients who underwent surgical resection.
  • METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify patients who were diagnosed with L-SCLC between 1988 and 2002 coded by SEER as localized disease (T1-T2Nx-N0) or regional disease (T3-T4Nx-N0).
  • Surgery was associated more commonly with T1/T2 disease (P < .001).
  • Surgery was associated with improved survival for both localized disease and regional disease with improvements in median survival from 15 months to 42 months (P < .001) and from 12 months to 22 months (P < .001), respectively.
  • Lobectomy was associated with the best outcome (P < .001).
  • Patients with localized disease who underwent lobectomy with had a median survival of 65 months and a 5-year OS rate of 52.6%; whereas patients who had regional disease had a median survival of 25 months and a 5-year OS rate of 31.8%.
  • On multivariate analysis, the benefit of surgery varied in a time-dependant fashion.
  • However, the benefit of lobectomy remained across all time intervals (P = .002).
  • CONCLUSIONS: The use of surgery, and particularly lobectomy, in selected patients with L-SCLC was associated with improved survival outcomes.
  • Future prospective studies should consider the role of surgery as part of the multimodality management of this disease.
  • [MeSH-major] Lung Neoplasms / surgery. Small Cell Lung Carcinoma / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. SEER Program. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082453.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Kawase A, Nagai K: [Treatment strategy for neuroendocrine carcinoma of the lung]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1619-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategy for neuroendocrine carcinoma of the lung].
  • Neuroendocrine carcinoma of the lung is classified into typical carcinoid (TC), atypical carcinoid (ATC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCLC).
  • The standard treatment of carcinoid tumor is surgical resection.
  • There is no standard therapy for LCNEC.
  • Generally, the treatment of LCNEC is surgical resection and postoperative adjuvant chemotherapy in stage I and II, concurrent chemo-radiotherapy in stage III, and combination chemotherapy in stage IV.
  • The treatment of SCLC is mainly combination chemotherapy.
  • Standard therapy of SCLC is concurrent chemo-radiotherapy in limited disease and combination chemotherapy in extensive disease.
  • Combination chemotherapy with cisplatin and etoposide is administered for limited disease, and cisplatin and irinotecan is administered for extensive disease.
  • The surgical indication for SCLC is only stage I patients.
  • Adjuvant chemotherapy is needed postoperatively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Neuroendocrine / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838019.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Gefitinib: a second look. Non-small cell lung cancer: still very disappointing. Prescrire Int; 2009 Aug;18(102):145-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
  • (1) In patients with non-small cell lung cancer, whatever the stage, the benefits of cytotoxic chemotherapy are limited.
  • There is no consensus second-line chemotherapy after failure of first-line platinum-based chemotherapy;.
  • (2) Gefitinib is an EGF (epidermal growth factor) receptor inhibitor available in France for named-patient compassionate treatment of non-small cell lung cancer when first-line chemotherapy fails;.
  • (4) Preliminary analysis of a placebo-controlled trial in 255 patients unexpectedly showed that adding gefitinib to chemoradiotherapy followed by docetaxel shortened median survival time, from 35 months with placebo to only 23 months (p=0.013).
  • Another trial in 603 patients showed no difference in survival between patients receiving 6 cycles of platinum-based chemotherapy versus patients receiving 3 cycles of the same chemotherapy followed by gefinitib[sic];.
  • (6) In second-line treatment, there are 4 unblinded trials versus docetaxel.
  • (8) In practice, there is no reason to use gefitinib in non-small cell lung cancer, except perhaps when there are no other available options and in a subgroup of patients who might benefit and who agree to participate in a comparative trial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Diarrhea / chemically induced. Drug Approval. France. Humans. Lung Diseases, Interstitial / chemically induced. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Skin Diseases / chemically induced. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19739343.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


39. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of esophagus: report of 9 cases and review of literature.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • Two patients had a stage IIa disease, five had a stage IIb disease, and the other two had a stage III disease of International Union Contrele Cancer (UICC).
  • Three of the nine resected specimens showed foci of squamous cell carcinoma in situ.
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • CONCLUSION: Primary small cell carcinoma of the esophagus is a rare but very malignant tumor.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down


40. Kong FM, Zhao L, Hayman JA: The role of radiation therapy in thoracic tumors. Hematol Oncol Clin North Am; 2006 Apr;20(2):363-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of radiation therapy in thoracic tumors.
  • Radiation plays an important role in the treatment of thoracic tumors.
  • During the last 10 years there have been several major advances in thoracic RT including the incorporation of concurrent chemotherapy and the application of con-formal radiation-delivery techniques (eg, stereotactic RT, three-dimensional conformal RT, and intensity-modulated RT) that allow radiation dose escalation.
  • Radiation as a local measure remains the definitive treatment of medically inoperable or surgically unresectable disease in NSCLC and part of a multimodality regimen for locally advanced NSCLC, limited stage SCLC, esophageal cancer, thymoma, and mesothelioma.
  • [MeSH-major] Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy / methods. Thoracic Neoplasms / radiotherapy
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / radiotherapy. Combined Modality Therapy. Esophageal Neoplasms / radiotherapy. Humans. Incidence. Mesothelioma / radiotherapy. Thymoma / radiotherapy. Thymus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730299.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 219
  •  go-up   go-down


41. Oka M, Fukuda M, Fukuda M, Kinoshita A, Kuba M, Ichiki M, Rikimaru T, Soda H, Takatani H, Narasaki F, Nagashima S, Nakamura Y, Hayashi N, Kohno S: Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer. Eur J Cancer; 2001 Jul;37(11):1359-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer.
  • We conducted a phase I study of irinotecan (CPT-11) and cisplatin with concurrent split-course radiotherapy in locally advanced stage III non-small cell lung cancer (NSCLC).
  • This study aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of this therapy.
  • Two chemotherapy cycles of CPT-11 (days 1, 8 and 15) and cisplatin (day 1) were repeated with a 28-day interval.
  • Radiotherapy of 2 Gy/day commenced on day 2 of each chemotherapy cycle, with 24 Gy and 36 Gy administered for the first and second cycle, respectively.
  • Dose escalation was limited to 60/80 mg/m(2) which was the recommended dose for CPT-11/cisplatin alone in NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy / methods. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11435065.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


42. Riedel RF, Crawford J: Small-cell lung cancer: a review of clinical trials. Semin Thorac Cardiovasc Surg; 2003 Oct;15(4):448-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell lung cancer: a review of clinical trials.
  • Small-cell lung cancer (SCLC) is expected to account for 25% of the approximate 170,000 cases of lung cancer diagnosed in the United States in 2002.
  • Although sensitive and responsive to chemotherapy, SCLC has an increased propensity for early metastases, with relapses being common and long-term survival rates being poor.
  • Clinical trials have played a vital role in expanding our knowledge base for this disease and have resulted in newer modalities, including chemotherapeutic agents, prophylactic cranial irradiation, and thoracic radiotherapy designed to improve overall outcomes.
  • Clinical trials have also served to clarify the role of surgery in a disease that traditionally has been thought to be nonoperable.
  • This review will focus on the results of clinical trials that have had an effect on the treatments of patients with limited and extensive-stage SCLC, with recommendations from the National Comprehensive Cancer Network being emphasized.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Clinical Trials as Topic / trends. Cranial Irradiation. Forecasting. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Thoracic Surgical Procedures. United States / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14710387.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


43. Ciombor KK, Rocha Lima CM: Management of small cell lung cancer. Curr Treat Options Oncol; 2006 Jan;7(1):59-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of small cell lung cancer.
  • Small cell lung cancer (SCLC) is an aggressive type of lung cancer characterized by rapid growth and early metastasis.
  • It is chemosensitive and radiosensitive, yet decades of research investigating multimodality treatments have failed to control or cure this disease in most patients.
  • First-line treatment of limited-stage disease consists of chemotherapy (often etoposide/cisplatin or etoposide/carboplatin) combined with thoracic radiation therapy (TRT), followed by prophylactic cranial irradiation to decrease brain metastases as a site of disease progression for those who experience complete remission or a very good partial response to multimodality treatment.
  • In a Japanese trial, the combination of irinotecan and cisplatin had initially shown promise in treating patients with extensive-stage SCLC, but a confirmatory trial in the United States did not find a difference in overall survival with irinotecan/cisplatin versus etoposide/cisplatin.
  • Adding a third drug to the etoposide/cisplatin combination, as well as other triplet therapies, has mostly been ineffective in improving outcomes.
  • Variables in chemotherapy administration, including maintenance therapy, alternating non-cross-resistance regimens, and dose intensification, have not been shown to increase survival at large.
  • In terms of radiation therapy, early administration of TRT concurrent with chemotherapy, and hyperfractionation, have been beneficial in treatment of limited-stage disease.
  • In patients who relapse, second-line therapy options consist of reinduction of previous chemotherapy or administration of a single agent.
  • Targeted biological therapies for SCLC are now being investigated, and although a great deal of research remains to be done, these agents and their derivatives may provide the most hope for future treatment of SCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Humans. Immunologic Factors / therapeutic use. Neoplasm Metastasis. Prognosis. Survival

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4665-72 [12488411.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4837-45 [15570087.001]
  • [Cites] Semin Oncol. 1994 Jun;21(3 Suppl 6):23-30 [8052870.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4434-9 [12431965.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1563-74 [2167954.001]
  • [Cites] Lung Cancer. 2000 Oct;30(1):23-36 [11008007.001]
  • [Cites] Br J Cancer. 1998;77(2):347-51 [9461009.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1519-30 [12377639.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1319-23 [10389914.001]
  • [Cites] Jpn J Clin Oncol. 1997 Jun;27(3):166-9 [9255271.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1):9-25 [12635086.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):336-44 [8381164.001]
  • [Cites] Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):11-2 [11221015.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):476-84 [10441603.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 4:S3-8 [14565508.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3947-55 [12351591.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Apr;18(2):499-518 [15094184.001]
  • [Cites] Oncology. 1996 Mar-Apr;53(2):169-72 [8604245.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] Lung Cancer. 2001 Sep;33 Suppl 1:S99-107 [11576714.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Eur J Nucl Med. 2001 Apr;28(4):483-8 [11357499.001]
  • [Cites] J Thorac Oncol. 2007 Nov;2(11):1036-41 [17975496.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3248-54 [15310768.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):666-74 [15870437.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):265-71 [9920950.001]
  • [Cites] Chest. 2001 Mar;119(3):950-4 [11243980.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1550-5 [12697880.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3054-60 [12118018.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):56-70 [12908137.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1743-9 [11251005.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):259S-271S [12527584.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1187-93 [15277257.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10 ):2594-9 [7595712.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3752-9 [15923572.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2681-91 [10561342.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1110-7 [15020613.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):539-45 [12056703.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Apr;18(2):323-41 [15094174.001]
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):136-40 [15075905.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):557-61 [11398892.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):183-90 [7707405.001]
  • (PMID = 16343369.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors
  • [Number-of-references] 55
  •  go-up   go-down


44. Ren S, Terman DS, Bohach G, Silvers A, Hansen C, Colt H, Sahn SA: Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest; 2004 Nov;126(5):1529-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
  • BACKGROUND: Malignant pleural effusion (MPE) may occur in up to 50% of patients with non-small cell lung cancer (NSCLC).
  • Since these patients are typically symptomatic from their MPE, prompt treatment is required.
  • Patients with symptomatic MPE from NSCLC and poor performance scores (Eastern Cooperative Oncology Group [ECOG] score >/= 2, Karnofsky performance status [KPS] score < 50) are generally not offered systemic chemotherapy.
  • Treatment is palliative and includes intrapleural catheter drainage or chemical pleurodesis with talc, doxycycline, or bleomycin.
  • OBJECTIVE: Our goal was to investigate the toxicity and therapeutic effect of a new therapeutic agent, Staphylococcus aureus superantigen (SSAg), a powerful T-cell stimulant administered intrapleurally to unselected, consecutive patients with MPE from NSCLC (stage IIIb with pleural effusion) and a poor performance status.
  • By providing direct access of the SSAg to the bronchial and mediastinal lymphatics, we predicted that intrapleural administration of SSAg would induce resolution of MPE and prolong survival in this population with advanced NSCLC and a limited prognosis.
  • METHODS: Fourteen consecutive, unselected patients with MPE from NSCLC and a median pretreatment KPS score of 40 (range, 10 to 60) received pleural instillation of SSAg, 100 to 400 pg, once or twice weekly (mean, 3.7 +/- 1.3 treatments [+/- SD]) until the pleural effusions resolved.
  • They were evaluated for drug toxicity, resolution, duration of MPE, and survival.
  • RESULTS: Other than mild fever (maximum grade 2), toxicity of SSAg treatment was trivial and notably devoid of respiratory distress or hypotension.
  • In 12 patients, the response endured for > 90 days, with a median time to recurrence of 5 months (range, 3 to 23 months).
  • The median survival for the SSAg-treated group was 7.9 months (range, 2 to 36 months; 95% confidence interval [CI], 5.9 to 11.4 months), compared to a median survival of 2.5 months (range, 0.1 to 57 months; 95% CI, 1.3 to 3.4 months) for 18 consecutive, unselected patients with MPE from NSCLC (stage IIIb) treated with talc poudrage (p = 0.044).
  • SSAg-treated patients with a median KPS of 40 (range, 10 to 60) had a median survival that exceeded that with talc poudrage, and was comparable to current systemic chemotherapy used in patients with KPS >/= 70 status.
  • SSAg treatment is simple to perform, minimally invasive, and does not require hospital time.
  • It may be an attractive alternative to existing palliative modalities for stage IIIb patients with MPE and poor performance who are not candidates for systemic chemotherapy.
  • [MeSH-major] Antigens, Bacterial / therapeutic use. Carcinoma, Non-Small-Cell Lung / complications. Enterotoxins / therapeutic use. Lung Neoplasms / complications. Pleural Effusion, Malignant / drug therapy. Staphylococcus

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Chest. 2011 Sep;140(3):835
  • (PMID = 15539723.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20-RR15587
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Enterotoxins; 39424-53-8 / enterotoxin B, staphylococcal
  •  go-up   go-down


45. El Sharouni SY, Kal HB, Barten-Van Rijbroek A, Struikmans H, Battermann JJ, Schramel FM: Concurrent versus sequential chemotherapy and radiotherapy in limited disease small cell lung cancer: a retrospective comparative study. Anticancer Res; 2009 Dec;29(12):5219-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent versus sequential chemotherapy and radiotherapy in limited disease small cell lung cancer: a retrospective comparative study.
  • BACKGROUND: Patients with limited-disease small cell lung cancer are treated with chemotherapy and chemotherapy combined with radiotherapy.
  • Treatment schemes with curative intention include sequential or concurrent chemoradiotherapy, both combined with prophylactic cranial irradiation (PCI).
  • PATIENTS AND METHODS: Until 2001, patients received 4-5 cycles of chemotherapy.
  • In cases of no complete response, palliative radiotherapy (RT) was given in 13 fractions of 3 Gy (CT-RT group, N=26).
  • A total of 89 patients did not receive RT after chemotherapy (CT group).
  • After complete response, curatively intended RT was given, of 16x2.5 Gy, concurrently with PCI of 15x2 Gy (SCT-RT group, N=111).
  • From 2001, 40 patients received 4-5 cycles of chemotherapy concurrently with RT of 25x1.8 Gy.
  • Endpoints were median survival time (MST) and overall survival (OS).
  • CONCLUSION: Concurrent chemoradiotherapy resulted in longer MST and higher OS than sequential chemoradiotherapy, chemotherapy with palliative radiotherapy or chemotherapy alone.
  • Results may improve further by applying PCI at an earlier stage and increasing the RT dose.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Small Cell Lung Carcinoma / drug therapy. Small Cell Lung Carcinoma / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Time Factors


46. Lebitasy MP, Hédelin G, Purohit A, Moreau L, Klinzig F, Quoix E: Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994. Br J Cancer; 2001 Sep 14;85(6):808-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994.
  • Recent analyses of series of small-cell lung cancer (SCLC) patients included in clinical trials have shown improved survival over time, but it has been impossible to determine whether this was due to selection biases, stage migration, or true therapeutic improvement.
  • To determine if there has been a true improvement of survival over time, we reviewed the medical records of all consecutive patients diagnosed with SCLC between 1981 and 1994 in the Bas-Rhin in France.
  • Among the 787 patients (median age 63), there was no significant period effect for sex, age, or stage.
  • The chemotherapy rate increased (from 76.4% in 1981-1983 to 91.7% in 1993-1994, P = 10(-5)) and mediastinal irradiation decreased (to roughly 25% of patients after 1983).
  • Median survival time increased for the overall population from 6.6 months in 1981-1983 to 11.3 months in 1993-1994 (P = 10(-5)), for patients with limited disease (LD) from 9.2 (P = 0.002) months to 14.0 months, and for those with extensive (ED) disease from 3.5 months to 9.6 months (P = 10(-5)).
  • Significant independent prognostic factors were disease extent, clinical trial participation, period, type of chemotherapy, and mediastinal irradiation in LD.
  • Survival time has truly improved as 'state of the art' management of SCLC has changed.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Lung Neoplasms / mortality. Lung Neoplasms / therapy
  • [MeSH-minor] Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. France / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] Ann Intern Med. 1978 Feb;88(2):194-9 [204239.001]
  • [Cites] Presse Med. 1995 Jan 28;24(4):217-21 [7899367.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1215-20 [7738624.001]
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):949-52 [7646928.001]
  • [Cites] Cancer. 1996 May 15;77(10):2032-8 [8640666.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):547-53 [9261523.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):901-12 [9379691.001]
  • [Cites] Eur J Cancer. 1997 Jun;33(7):1075-107 [9376190.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):57-65 [9486464.001]
  • [Cites] Ann Oncol. 1998 May;9(5):543-7 [9653496.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2191-6 [10070286.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1867-76 [10547562.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1794-801 [10561217.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):8-15 [10883661.001]
  • [Cites] Cancer Treat Rep. 1981 Sep-Oct;65(9-10):767-74 [6268294.001]
  • [Cites] Cancer Treat Rep. 1983 Jan;67(1):37-43 [6311413.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Jun 2;288(6431):1643-6 [6326932.001]
  • [Cites] J Clin Oncol. 1984 Dec;2(12):1359-65 [6096518.001]
  • [Cites] J Clin Oncol. 1985 Jan;3(1):80-91 [2981294.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1142-7 [4020412.001]
  • [Cites] J Clin Oncol. 1985 Nov;3(11):1471-7 [2997406.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):4189-94 [3015384.001]
  • [Cites] J Clin Oncol. 1986 Sep;4(9):1314-20 [3018183.001]
  • [Cites] N Engl J Med. 1987 Apr 9;316(15):912-8 [3029592.001]
  • [Cites] J Clin Oncol. 1987 Dec;5(12):1864-73 [2824708.001]
  • [Cites] CA Cancer J Clin. 1988 Jan-Feb;38(1):5-22 [3123025.001]
  • [Cites] Am J Med. 1988 Aug;85(2):194-6 [2840825.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1264-70 [2842464.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):344-54 [2537384.001]
  • [Cites] Br J Cancer. 1990 Apr;61(4):597-604 [2158808.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1042-9 [2161447.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1563-74 [2167954.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 19;83(12):855-61 [1648142.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):986-92 [1648949.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1639-49 [1651996.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):282-91 [1310103.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):890-5 [1316951.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1618-24 [1331787.001]
  • [Cites] Lung Cancer. 2000 Nov;30(2):127-34 [11086206.001]
  • [Cites] Am J Med. 1969 Apr;46(4):516-25 [5791000.001]
  • [Cites] Lancet. 1973 Jul 14;2(7820):63-5 [4123619.001]
  • [Cites] Cancer Chemother Rep 3. 1973 Mar;4(2):31-42 [4580860.001]
  • [Cites] Cancer. 1994 Oct 1;74(7 Suppl):2208-14 [8087794.001]
  • (PMID = 11556829.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Other-IDs] NLM/ PMC2375085
  •  go-up   go-down


47. Sirzén F, Kjellén E, Sörenson S, Cavallin-Ståhl E: A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol; 2003;42(5-6):493-515
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic overview of radiation therapy effects in non-small cell lung cancer.
  • A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU).
  • This synthesis of the literature on radiation therapy for non-small cell lung cancer (NSCLC) is based on data from 4 meta-analyses and 31 randomized trials.
  • The results were compared with those of a similar overview from 1996 including 28 172 patients.
  • The conclusions reached can be summarized as follows: Extensive clinical experience indicates that radiotherapy for medically inoperable patients or patients refusing surgery with NSCLC stage I/II prolongs survival, 15 -20% of these patients reaching long-term (5-year) survival.
  • There is strong evidence that postoperative radiotherapy in radically resected stage I/II NSCLC does not prolong survival compared with observation alone.
  • There is some evidence that continuous hyperfractionated accelerated radiotherapy (CHART) is associated with increased survival compared to conventional radiotherapy in locally advanced NSCLC and also in medically unfit patients with stage I/II NSCLC.
  • However, the benefit is limited to squamous cell histology.
  • There is strong evidence that combined modality treatment with platinum-based chemotherapy and radiotherapy, either neoadjuvant or concomitant, is superior to radiotherapy alone in terms of survival in locally advanced unresectable NSCLC and should be the standard of care in patients with good performance status.
  • There is some evidence that concomitant chemo-radiotherapy is associated with increased survival compared with sequential chemo-radiotherapy, albeit at the price of increased toxicity Comment: Combined chemo-radiotherapy of primary non-resectable stage III NSCLC followed by surgery in responders lacks evidence from prospective randomized trials and cannot be recommended for routine use.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / methods. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Sweden. Treatment Outcome


48. Yashiki C, Hirose T, Sugiyama T, Kusumoto S, Shirai T, Ohmori T, Adachi M, Nakamura A: [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer]. Gan To Kagaku Ryoho; 2010 Feb;37(2):245-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
  • We examined the association between chemotherapy-induced myelosuppression and prognosis in limited-stage disease small cell lung cancer (LD SCLC).
  • We retrospectively analyzed 76 patients with LD SCLC who received combination cisplatin or carboplatin of etoposide or irinotecan.
  • Patients were categorized into two groups (grade 0 to 2 or grade 3 to 4) according to the worst neutropenia, anemia, or thrombocytopenia during first-line chemotherapy and were analyzed for overall survival (OS) and time to progression (TTP).
  • From univariate analysis, OS was significantly better in patients who developed grade 0 to 2 anemia or thrombocytopenia than those who developed grade 3 to 4.
  • Myelosuppression during chemotherapy is not a prognostic factor in LD SCLC.
  • Our results show doses of platinum doublet chemotherapy were adequate in patients with LD SCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Diseases / chemically induced. Granulocyte Precursor Cells / drug effects. Lung Neoplasms / drug therapy. Small Cell Lung Carcinoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Middle Aged. Platinum Compounds / administration & dosage. Platinum Compounds / adverse effects. Platinum Compounds / therapeutic use. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154478.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Platinum Compounds; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


49. Gridelli C, Maione P, Rossi A: Treatment of stage I-III non-small-cell lung cancer in the elderly. Oncology (Williston Park); 2006 Apr;20(4):373-80; discussion 385-6, 388, 393 passim
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of stage I-III non-small-cell lung cancer in the elderly.
  • Elderly patients with stage I-III non-small-cell lung cancer (NSCLC) constitute a peculiar patient population and need specific therapeutic approaches.
  • Limited resections are an attractive alternative for elderly patients with resectable NSCLC because of the potential reduction in postoperative complications.
  • Curative radiation therapy is an acceptable alternative for elderly patients who are unfit for or refuse surgery.
  • Hypofractionated stereotactic body radiation therapy is of particular interest for this population because of its favorable tolerance.
  • Elderly patients may tolerate chemotherapy poorly because of comorbidity and organ failure.
  • The survival benefit obtained with adjuvant platinum-based chemotherapy in the younger population may vanish or decrease in the elderly because of a potential higher toxic death rate or lower compliance to treatment.
  • The efficacy and feasibility of adjuvant chemotherapy for elderly patients need to be investigated in specific trials.
  • Neoadjuvant chemotherapy remains an experimental approach under investigation in the general patient population, and consequently should not be considered in clinical practice in the elderly.
  • Only specifically designed prospective studies will elucidate the real role and feasibility of this combined approach in the treatment of unselected elderly patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Etoposide / therapeutic use. Humans. Neoadjuvant Therapy


50. Hanna N, Ansari R, Fisher W, Shen J, Jung SH, Sandler A: Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. Lung Cancer; 2002 Mar;35(3):293-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study.
  • Results of a previous Hoosier Oncology Group (HOG) study revealed a small survival advantage for VIP versus etoposide and cisplatin (EP) for patients with extensive stage small cell lung cancer (SCLC).
  • This phase II study evaluated VIP with concurrent thoracic radiotherapy in patients with limited stage SCLC.
  • Eligible patients had a Karnofsky Performance Score > or = 50, no prior chemotherapy or radiotherapy, and adequate end organ function.
  • Radiotherapy was given as a daily fraction of 1.8 Gy, five fractions per week for 5 weeks for a total dose of 45 Gy, beginning on day 1 of VIP.
  • The first 13 patients received etoposide 75 mg/m(2), cisplatin 20 mg/m(2), and ifosfamide 1.2 g/m(2) on days 1-4 with Mesna every 3 weeks for four cycles unless the patient demonstrated disease progression or undue toxicity.
  • There were four treatment-related deaths [three patients (23%) on the 4-day regimen and one patient (2.5%) on the 3-day regimen].
  • In addition, treatment-related morbidity and mortality appears to be unacceptably high with the VIP regimen.
  • [MeSH-major] Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Cisplatin / therapeutic use. Combined Modality Therapy / methods. Etoposide / therapeutic use. Ifosfamide / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11844604.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


51. Souquet PJ, Gérinière L: [Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine]. Rev Pneumol Clin; 2000 Nov;56(5):315-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine].
  • [Transliterated title] Chimiothérapie des cancers du poumon non à petites cellules de stade IV. Apport de la gemcitabine.
  • Several drugs active against non-small-cell lung cancer currently available.
  • The cisplatin-gemcitabine combination can now be considered as a new "classical" activ regimen in stage IV NSCLC patients and could be used in patients with more favorable prognosis (i.e. in the periopertive seeting).
  • Nevertheless, the benefit of such treatment in stage IV NSCLC seems to be limited to patients with a good performance status (PS 0 and 1).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Humans. Ifosfamide / administration & dosage. Mitomycin / administration & dosage. Paclitaxel / administration & dosage. Prognosis. Randomized Controlled Trials as Topic. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11139761.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 23
  •  go-up   go-down


52. He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J: Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer; 2009 Nov 15;125(10):2393-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
  • The high frequency of epidermal growth factor receptor (EGFR) mutations in tyrosine kinase inhibitor-responsive non-small-cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating EGFR mutations in guiding the clinical use of EGFR-targeted therapies.
  • However, specimen source and methods for EGFR mutation analysis are limited by tissue availability and technical feasibility in clinical application.
  • Therefore, the current study is designed to establish a blood-based approach for the assessment of EGFR mutations in NSCLC patients, in particular the advanced stage, and to test its clinical application.
  • The detection rate of the EGFR exon19 deletions and exon21 L858R was 49.3% (66/134) by the blood-based, mutant-enriched polymerase chain reaction.
  • In the paired tumor and plasma samples, the detected mutant types of each pair respectively by direct sequencing and mutant-enriched polymerase chain reaction were concordant in 17 of 18 (94.4%).
  • In the patients treated with gefitinib as a second-line therapy, those with plasma EGFR mutation have a prolonged median progression-free survival compared with those with EGFR wild type (7.609 vs. 2.877 months, p = 0.002).
  • These results suggest that the blood-based EGFR mutations test has the ability to provide a reliable guidance for clinical decision making for the treatment of the advanced NSCLC patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation / genetics. Polymerase Chain Reaction / methods. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / blood. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate


53. Sas-Korczyńska B, Korzeniowski S, Wójcik E: Comparison of the effectiveness of "late" and "early" prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Strahlenther Onkol; 2010 Jun;186(6):315-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the effectiveness of "late" and "early" prophylactic cranial irradiation in patients with limited-stage small cell lung cancer.
  • PURPOSE: To evaluate the effectiveness of timing of application of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer in limited stage of disease (LS SCLC).
  • PATIENTS AND METHODS: Between 1995 and 2004, 129 patients with LS SCLC were treated within two consecutive phase II studies assessing different schedules of combined treatment.
  • All patients received chemotherapy and concurrent thoracic radiotherapy.
  • In 86 patients (66.7%) who developed complete response in the thorax, PCI was performed either after chemoradiotherapy ("late" PCI , n = 45 [52.4%]) or during chemoradiotherapy ("early" PCI, n = 41 [47.7%]).
  • In the latter case, PCI was given immediately after the end of thoracic radiotherapy and prior to the last cycles of chemotherapy to a total dose of 30 Gy in 2-Gy fractions to the whole brain.
  • The results were evaluated with regard to 4-year rates of overall survival, disease-free survival, and brain metastases-free survival.
  • Additionally, the prognostic role of PCI application and its time delay in relation to survival rates and incidence of brain metastases was estimated.
  • RESULTS: The 4-year survival rates were 25.5% for overall survival, 26.8% for disease-free survival, and 67.8% for brain metastases-free survival.
  • During the observation period, 32 patients (24.8%) developed brain metastases, which occurred in 20 of 43 patients (46.5%) without and only in twelve out of 86 patients (14%) with PCI.
  • The 4-year brain metastases-free survival rates were 81.8%, if PCI was applied, versus 32.2%, if no such procedure was used (for p = 0.0000).
  • CONCLUSION: PCI significantly decreases the incidence of brain metastases and delays their development in patients with LS SCLC.
  • "Early" PCI is more effective than PCI applied after combined therapy.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / secondary. Cranial Irradiation. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2008 Feb;184(2):61-6 [18259696.001]
  • [Cites] Strahlenther Onkol. 1993 Jun;169(6):329-38 [8391171.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):179-82 [7642416.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(11):1752-8 [9470828.001]
  • [Cites] Int J Radiat Biol. 2003 Jul;79(7):495-502 [14530157.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Nov;52(2):117-26 [15501076.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):246-54 [3027269.001]
  • [Cites] Ann Oncol. 2002 May;13(5):748-54 [12075744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):626-33 [12788167.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4837-45 [15570087.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):252-8 [12082684.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):801-6 [14770437.001]
  • [Cites] BMC Cancer. 2001;1:5 [11432756.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4137-45 [17827464.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):309-16 [11380216.001]
  • [Cites] Strahlenther Onkol. 2008 May;184(5):251-5 [18427755.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):797-806 [9531363.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):447-51 [1311025.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):476-84 [10441603.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 4):23-6 [11479893.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1618-24 [1331787.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):68-74 [11777623.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1):38-46 [12635088.001]
  • [Cites] Strahlenther Onkol. 2008 Jan;184(1):30-5 [18188520.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12):647-54 [19107345.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1):26-37 [12635087.001]
  • [Cites] Lung Cancer. 2004 Jul;45(1):105-17 [15196740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Mar;12(3):385-9 [3007408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):911-4 [7860405.001]
  • [Cites] Oncologist. 2000;5(4):293-8 [10964996.001]
  • [Cites] Clin Lung Cancer. 2007 May;8(6):365-8 [17562236.001]
  • [Cites] Strahlenther Onkol. 1996 Oct;172(10):553-8 [8966672.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Feb;49(2):119-33 [15012973.001]
  • [Cites] Strahlenther Onkol. 1999 Dec;175(12):621-3 [10633791.001]
  • [Cites] Cancer Treat Rev. 2004 Oct;30(6):521-43 [15325033.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):153-60 [9266453.001]
  • (PMID = 20495970.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Laurie SA, Kris MG, Portlock CS, Rosenzweig KE, Miller VA, Krug LM, Rusch VW: The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease. Cancer; 2002 Jul 1;95(1):119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.
  • BACKGROUND: The objective of this study was to document the natural history of second lung carcinomas, common second tumors that arise in survivors of Hodgkin disease (HD).
  • METHODS: The data bases of the Memorial Sloan-Kettering Cancer Center were searched to retrieve those patients who were listed with a diagnosis of both lung carcinoma and HD.
  • Information was extracted regarding their HD (including age at diagnosis and treatment received) and their lung carcinoma (including smoking history, latency from HD, histology, disease stage, treatment received, treatment response, and survival).
  • RESULTS: Twenty-one lung carcinomas were diagnosed in 19 patients, with a median latency of 13 years from the time of diagnosis of HD.
  • Only five patients underwent complete resection, and four patients were alive and disease free at the last follow-up.
  • In contrast, the median survival of 14 patients with unresectable disease was 3 months.
  • No major objective responses were documented after chemotherapy.
  • Poor performance status and prior thoracic radiotherapy limited treatment in patients with advanced disease.
  • All patients had either received radiotherapy to the chest for HD or had a history of smoking; 74% of patients had both risk factors for the development of lung carcinoma.
  • CONCLUSIONS: In patients with a history of HD, survival after the development of lung carcinoma is poor.
  • Because surgical resection can lead to long-term survival, early detection is crucial.
  • HD survivors, especially those with a history of smoking, should undergo careful surveillance for second primary lung carcinomas and other diseases.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Hodgkin Disease / complications. Lung Neoplasms / therapy. Neoplasms, Second Primary / therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115325.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Fahim A, Butt M, McGivern DV: A case of limbic encephalitis presenting as a paraneoplastic manifestation of limited stage small cell lung cancer: a case report. J Med Case Rep; 2010;4:408
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of limbic encephalitis presenting as a paraneoplastic manifestation of limited stage small cell lung cancer: a case report.
  • INTRODUCTION: The differential diagnosis of altered mental status and behavioral change is very extensive.
  • Paraneoplastic limbic encephalitis is a rare cause of cognitive impairment, which should be considered in the differential diagnosis.
  • CASE PRESENTATION: A 64-year-old British Caucasian woman presented to our hospital with a 12-week history of confusion and short-term memory loss.
  • She was hyponatremic with a serum sodium level of 128mmol/L.
  • A thoracic computed tomography scan showed left hilar opacity with confluent lymphadenopathy.
  • A percutaneous biopsy confirmed a diagnosis of small cell lung cancer.
  • There was no radiological evidence of brain metastasis on the computed tomography scan.
  • It showed hyperintense signals from both hippocampi, highly suggestive of limbic encephalitis presenting as a paraneoplastic manifestation of small cell lung cancer.
  • She had a significant radiological and clinical response following chemotherapy and radiotherapy.
  • CONCLUSION: This case highlights the importance of considering paraneoplastic syndromes in patients with neurological symptoms in the context of lung malignancy.
  • If initial investigations fail to reveal the cause of cognitive impairment in a patient with malignancy, magnetic resonance imaging may be invaluable in the diagnosis of limbic encephalitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 2003 Nov;78(11):1363-8 [14601695.001]
  • [Cites] Brain. 1968 Sep;91(3):481-96 [5723018.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1084-8 [1963440.001]
  • [Cites] Tidsskr Nor Laegeforen. 2007 Nov 29;127(23):3077-80 [18049499.001]
  • (PMID = 21167030.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3018402
  •  go-up   go-down


56. De Marinis F, Migliorino MR, Paoluzzi L, Portalone L, Ariganello O, Cortesi E, Gamucci T, Gasperoni S, Cipri A, Martelli O, Nelli F, Foundation for Oncological Research: Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer; 2003 Mar;39(3):331-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.
  • OBJECTIVE: The objectives of this phase I/II study were to define the maximum tolerated dose (MTD), safety, and activity of cisplatin, etoposide, and gemcitabine (PEG) in the treatment of previously untreated patients with small-cell lung cancer (SCLC).
  • RESULTS: From September 1998 to April 2000, 56 patients with limited- or extensive-stage SCLC were enrolled and received a total of 235 cycles.
  • The median duration of response and median survival were 8.0 and 10 months, respectively, with a 1-year survival probability of 37.5%.
  • CONCLUSIONS: The combination of PEG is feasible and well tolerated as front-line chemotherapy in SCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Survival. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12609572.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


57. Bunn PA Jr: Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer; 2004 Sep;6(2):85-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
  • The most effective treatment for patients with early-stage non-small-cell lung cancer (NSCLC) remains complete surgical resection, providing the disease is medically operable and adequately staged.
  • The effectiveness of surgical resection, however, is limited by high rates of distant recurrence caused by the presence of metastatic disease that is not apparent at the time of surgery.
  • Thus, induction, adjuvant chemotherapy, and radiation therapy, as well as a combination of both, have been studied for their ability to reduce local and distant recurrence rates and to improve survival.
  • Adjuvant chest radiation therapy following resection decreases local relapse rates but also decreases overall patient survival, with an increase in the hazard ratio of death.
  • A previous metaanalysis of cisplatin-based adjuvant chemotherapy showed a 13% reduction in the hazard ratio of death and a 5% improvement in 5-year survival, but the differences in the small sample failed to reach statistical significance.
  • Newer 2-drug combinations were shown to reduce the hazard ratio of death by 14%, with a 4.3% improvement in 5-year survival in the largest trial recently reported.
  • These newer 2-drug combinations also have the benefits of reduced toxicity and improved delivery.
  • Induction chemotherapy offers several potential advantages compared with adjuvant chemotherapy, such as improved delivery, early control of micrometastatic disease, and reduction of the primary tumor size prior to surgery, thus allowing for more conservative and possibly complete resection of the tumor.
  • A number of clinical trials have shown that induction chemotherapy is safe and feasible, with no significant increase in surgical complications, and results in favorable survival rates in patients with resectable NSCLC.
  • A number of phase III randomized trials are currently under way to confirm the benefits of induction chemotherapy in patients with stage IB-IIIA NSCLC and to compare induction chemotherapy versus adjuvant chemotherapy following surgery versus surgery alone.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Therapy / methods. Chemotherapy, Adjuvant. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Pneumonectomy / methods. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome


58. Murray N: Small-cell lung cancer at the millennium: radiotherapy innovations improve survival while new chemotherapy treatments remain unproven. Clin Lung Cancer; 2000 Feb;1(3):181-90; discussion 191-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell lung cancer at the millennium: radiotherapy innovations improve survival while new chemotherapy treatments remain unproven.
  • Because of the systemic nature of small-cell lung cancer, one could predict that treatment advances would mainly come from innovations of chemotherapy.
  • Although combination chemotherapy is better than monotherapy, a clearly superior multidrug regimen has not emerged.
  • Investigations of more intensive chemotherapy with increased drug diversity and delivery have not prospered, and advantages of regimens including new agents have not yet been demonstrated in controlled trials.
  • As we enter the new millennium, twenty-five years have passed since the publication of studies describing the combined used of cyclophosphamide, doxorubicin, and vincristine for small-cell lung cancer.
  • It has been almost 20 years since the publication of the combination of etoposide and cisplatin became the widely accepted standard for the treatment of small-cell lung cancer.
  • Today, both treatment regimens continue to be widely used as standard therapy.
  • Ironically, proven advances in this systemic disease have been associated with innovations of local therapy.
  • Data from limited-stage small-cell lung cancer clinical trials published during the 1990s demonstrated that a number of radiotherapy interventions had significant survival benefits.
  • These radiotherapy interventions include addition of thoracic irradiation to chemotherapy, early delivery of thoracic irradiation concurrently with chemotherapy, more intense thoracic irradiation, and prophylactic cranial irradiation.
  • As we await improved systemic therapy in the next millennium, the prognosis for extensive-stage disease remains guarded, and adherence to optimal radiotherapy detail remains crucial for routine management of limited-stage patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14733641.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Yee D, Danielson B, Roa W: Combined modality treatment of limited stage small cell carcinoma of the lung. Rev Recent Clin Trials; 2008 May;3(2):150-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality treatment of limited stage small cell carcinoma of the lung.
  • Small cell lung carcinoma comprises approximately 10-20% of all lung cancers.
  • At the time of diagnosis, 20-30% of patients have what is considered limited stage disease.
  • Historically, chemotherapy has been the mainstay of treatment for small cell lung cancer, but more recent evidence from large meta-analyses have established the local control and overall survival advantages conferred by the addition of external beam thoracic radiotherapy in combination with chemotherapy for limited stage disease along with prophylactic cranial irradiation for complete responders.
  • At present, radiotherapy is recommended to commence in concurrentoe with an earlier cycle of chemotherapy.
  • Despite the established role of thoracic radiotherapy combined with chemotherapy for patients with limited stage disease, the optimal radiotherapy dose-fractionation schedule is still undefined.
  • Recent investigational radiotherapy approaches applied to limited stage small cell lung cancer patients include hyperfractionated radiotherapy, dose-escalated daily radiotherapy, and hypofractionation.
  • While several chemotherapy regimens and targeted systemic agents have been investigated in small numbers of small cell lung cancer patients, cisplatin with etoposide remains the current standard chemotherapy regimen for this cancer.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474026.001).
  • [ISSN] 1574-8871
  • [Journal-full-title] Reviews on recent clinical trials
  • [ISO-abbreviation] Rev Recent Clin Trials
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Number-of-references] 66
  •  go-up   go-down


60. Zereu M, Vinholes JJ, Zettler CG: p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin Lung Cancer; 2003 Mar;4(5):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer.
  • Small-cell lung cancer (SCLC) has a poor prognosis despite good initial response to chemotherapy.
  • Therefore, it is important to identify molecular markers that might influence survival and serve as potential therapeutic targets.
  • Previous studies have demonstrated immunohistochemical expression of p53 and Bcl-2 in approximately 40%-90% and 55%-90% of patients with SCLC, respectively, but its relationship with prognosis remains controversial.
  • To determine the correlation between the expression of p53 and Bcl-2 and disease-free survival, age (< 70 vs. >or= 70 years), sex, clinical stage (limited vs. extensive), performance status (World Health Organization stages 0-4), and weight loss (10% of body weight), we retrospectively studied 58 SCLC parafin sections of transbronchial biopsy specimens immunostained using monoclonal antibody against N-terminus of the human p53 protein and monoclonal antibody against Bcl-2 oncoprotein. p53 and Bcl-2 expression were observed in 41% and 57% of patients, respectively. p53 and Bcl-2 expression were not correlated with disease-free survival.
  • There was a significant correlation of p53 (P < 0.001) and Bcl-2 (P < 0.045) expressions with limited-stage disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Lung Cancer. 2003 Mar;4(5):303 [14609449.001]
  • (PMID = 14609448.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Decoster L, Stroobants S, Verbeken E, Nackaerts K, Vansteenkiste J: An unexpected abdominal 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) in a patient with limited stage small cell lung cancer. J Thorac Oncol; 2008 Feb;3(2):174-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unexpected abdominal 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) in a patient with limited stage small cell lung cancer.
  • We report the case of an unexpected 18F-fluorodeoxyglucose-avid lesion in the right lower abdomen in a patient with otherwise "very limited" (T1N0) small cell lung cancer (SCLC).
  • The patient was treated for presumed very limited disease SCLC, with resection, adjuvant chemotherapy, and prophylactic brain irradiation.
  • Follow-up fusion positron emission tomography-computed tomography revealed an unusual SCLC complication.
  • [MeSH-major] Appendiceal Neoplasms / radionuclide imaging. Carcinoma, Small Cell / radionuclide imaging. Diagnostic Errors / prevention & control. Lung Neoplasms / pathology. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303440.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Movsas B, Moughan J, Komaki R, Choy H, Byhardt R, Langer C, Goldberg M, Graham M, Ettinger D, Johnstone D, Abrams R, Munden R, Starkschall G, Owen J: Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol; 2003 Dec 15;21(24):4553-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy patterns of care study in lung carcinoma.
  • PURPOSE: For the first time, a lung Patterns of Care Study was conducted to determine the national patterns of radiation (RT) practice in patients treated for nonmetastatic lung cancer in 1998 to 1999.
  • MATERIALS AND METHODS: A national survey of randomly selected RT institutions in the United States was conducted using two-stage cluster sampling, stratified by practice type.
  • Patients with nonmetastatic lung cancer (Karnofsky performance score [KPS] > or = 60), who received RT as definitive or adjuvant therapy, were randomly selected.
  • RESULTS: The histologies were small-cell lung cancer (SCLC) in 14.5% of patients versus non-small-cell lung cancer (NSCLC) in 85.5% of patients.
  • Bone scans and brain imaging were not obtained in 34% and 52% of clinical stage (CS) III NSCLC patients, respectively.
  • Regarding treatment strategies, for SCLC and CS III NSCLC, chemotherapy plus RT was used significantly more than RT alone (P <.05); in CS I NSCLC, RT alone was the primary treatment (P <.05).
  • Overall, 58% of patients received systemic therapy.
  • On multivariate analysis, factors correlating with increased use of chemotherapy included younger age, histology (SCLC > NSCLC), increasing CS, increasing KPS, and lack of comorbidities.
  • CONCLUSION: This study establishes the general patterns of care for lung carcinoma in RT facilities within the United States.
  • As supported by clinical trials, patients with limited-stage SCLC and CS III NSCLC received chemotherapy plus RT more than they received RT alone.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy. Practice Patterns, Physicians'

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Dec 15;21(24):4479-80 [14597747.001]
  • (PMID = 14597743.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 65435
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


63. Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF Jr, Kozelsky TF, Jett JR: Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):995-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
  • PURPOSE: The primary goal was to identify the maximum tolerable dose (MTD) of thoracic radiation therapy (TRT) that can be given with chemotherapy and amifostine for patients with limited-stage small-cell lung cancer (LSCLC).
  • METHODS AND MATERIALS: Treatment began with two cycles of topotecan (1 mg/m(2)) Days 1 to 5 and paclitaxel (175 mg/m(2)) Day 5 (every 3 weeks) given before and after TRT.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336213.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA35103; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / UG1 CA189808; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Akerley W 3rd: Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest; 2000 Apr;117(4 Suppl 1):152S-155S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule.
  • STUDY OBJECTIVES: Sequential phase I and phase II trials of paclitaxel using an extended weekly schedule were performed to explore its effect on tolerance, limits of dose intensity, and activity at maximum dose intensity in disseminated non-small cell lung cancer (NSCLC).
  • DESIGN: Patients with stage IIIB/IV NSCLC were eligible if they had a performance status of 0 to 2, no previous chemotherapy, and normal organ function.
  • Paclitaxel was administered as a 3-h infusion weekly for 6 weeks of an 8-week cycle.
  • Doses were modified for toxicity observed on the day of treatment.
  • Dose escalation was limited primarily by neutropenia, and a relationship between dose and response was noted.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / administration & dosage. Radiation-Sensitizing Agents / administration & dosage
  • [MeSH-minor] Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Nervous System Diseases / chemically induced. Neutropenia / chemically induced. Platelet Count / drug effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10777471.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


65. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, Marks RS, Liu Y, Yang P: Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer; 2010 Feb;67(2):221-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients.
  • Combined modality therapy is the standard care for limited stage-small cell lung cancer (LS-SCLC) and has led to a significant improvement in patients' survival.
  • This study sought to investigate and define the importance of prognostic effects of known and controversial factors especially the impact of smoking status and treatment strategies.
  • A total of 284 patients with LS-SCLC were diagnosed and prospectively followed from 1997 to 2008 at Mayo Clinic; their characteristics and survival outcome were assessed on the basis of age, gender, smoking history, performance status (PS), tumor recurrence or progression, and treatment using Cox proportional hazards models.
  • (1) Although neither smoking status (former or current smokers) nor intensity (pack-years smoked) at the time of SCLC diagnosis were significant survival predictors, compared to continued smokers (who never quit smoking), patients who quit at or after diagnosis cut the risk of death by 45% (HR=0.55, 95% CI 0.38-0.79); patients who quit before lung cancer diagnosis also experienced survival benefit (HR=0.72, 95% CI 0.52-1.00). (2) Thoracic radiotherapy and platinum-based chemotherapy could significantly improve survival but the timing (within or after one month of diagnosis) of starting chemotherapy or radiation therapy did not. (3) After adjusting for other known factors, a lower PS did not predict poorer survival, suggesting that PS should not be the only factor for making treatment decisions.
  • In conclusion, this study demonstrated the negative impact of continued cigarette smoking on survival; therefore, clinicians and all care providers should strongly encourage smoking cessation at diagnosis of LS-SCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Nat Med. 2001 Jul;7(7):833-9 [11433349.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1953-60 [11064352.001]
  • [Cites] Head Neck. 2001 Oct;23(10):860-70 [11592233.001]
  • [Cites] Ann Oncol. 2002 May;13(5):748-54 [12075744.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1528-38 [12237922.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1321-30 [12654444.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1544-9 [12697879.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3201-6 [12874270.001]
  • [Cites] Lung Cancer. 2004 Jan;43(1):7-16 [14698532.001]
  • [Cites] Lung Cancer. 2004 Feb;43(2):127-34 [14739032.001]
  • [Cites] JAMA. 1980 Nov 14;244(19):2175-9 [6252357.001]
  • [Cites] N Engl J Med. 1987 Apr 9;316(15):912-8 [3029592.001]
  • [Cites] Eur Respir J. 1988 Dec;1(10):932-7 [2852124.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):344-54 [2537384.001]
  • [Cites] Br J Cancer. 1990 Apr;61(4):597-604 [2158808.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1563-74 [2167954.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):336-44 [8381164.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12233-7 [7991611.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):821-8 [8622030.001]
  • [Cites] Carcinogenesis. 1998 Apr;19(4):551-6 [9600337.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):476-84 [10441603.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):453-7 [10521057.001]
  • [Cites] Lung Cancer. 2005 Feb;47(2):165-72 [15639715.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] Chin Med J (Engl). 2005 Aug 5;118(15):1258-62 [16117878.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1370-8 [16365874.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6332-7 [16601104.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3815-6 [16921030.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3823-30 [16921033.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4539-44 [17008692.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4686-94 [17699846.001]
  • [Cites] N Engl J Med. 2007 Aug 16;357(7):664-72 [17699816.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):808-15 [11556829.001]
  • (PMID = 19497635.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 115857; United States / NCI NIH HHS / CA / R01 CA115857; United States / NCI NIH HHS / CA / R01 CA084354-08; United States / PHS HHS / / 84354; United States / NCI NIH HHS / CA / R01 CA084354; United States / NCI NIH HHS / CA / R01 CA 80127; United States / NCI NIH HHS / CA / R01 CA080127-09; United States / NCI NIH HHS / CA / R01 CA080127; United States / NCI NIH HHS / CA / CA115857-04; United States / NCI NIH HHS / CA / R01 CA115857-04; United States / NCI NIH HHS / CA / CA084354-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS114302; NLM/ PMC2815153
  •  go-up   go-down


66. Kluetz PG, Edelman MJ: Successful treatment of small cell lung cancer during pregnancy. Lung Cancer; 2008 Jul;61(1):129-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of small cell lung cancer during pregnancy.
  • This issue is of increasing importance in lung cancer given the rising number of cases of lung cancer in women, many of childbearing age.
  • Treatment with chemotherapy in patients who are pregnant is indicated in scenarios where the malignancy is aggressive and the risk of death of the mother outweighs the risk of fetal effects from chemotherapy.
  • We report a case of a pregnant female with limited stage small cell lung carcinoma treated at 27 weeks gestation with cisplatin and etoposide and subsequent delivery of a healthy child.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Pregnancy Complications / drug therapy


67. Passlick B: Can surgery improve local control in small cell lung cancer? Lung Cancer; 2001 Sep;33 Suppl 1:S147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can surgery improve local control in small cell lung cancer?
  • Current therapy for small cell lung cancer (SCLC) consists of chemotherapy with or without radiotherapy.
  • Radiotherapy is generally accepted as an essential treatment component of limited stage disease.
  • Furthermore, despite having obtained a complete radiographic response, up to 75% of these patients will have residual disease in the tumor specimen, if resection is performed.
  • Therefore, more effective means are needed to eradicate the primary tumor and to obtain an improved local disease control.
  • Recent phase two trials of multimodal regimens for stage I-IIIA SCLC demonstrate that in selected patients with early stage SCLC the combination of surgery and chemotherapy with or without radiotherapy is feasible with low morbidity and mortality rates.
  • The combination therapy results in satisfying long term outcome depending on the pathological tumor stage and a local disease control is achieved in almost all patients.
  • In order to confirm these promising results, a German multicenter prospective randomized phase III trial has been designed for patients with stage I-IIIA SCLC consisting of induction chemotherapy, followed by surgery, adjuvant thoracic radiotherapy and prophylactic cranial radiation compared to thoracic radiotherapy and prophylactic cranial radiation.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11576721.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 20
  •  go-up   go-down


68. Brown PD, Bonner JA, Foote RL, Frytak S, Marks RS, Richardson RL, Creagan ET: Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancer. Am J Clin Oncol; 2001 Dec;24(6):556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a phase I/II study of high-dose thoracic radiotherapy with concomitant cisplatin and etoposide in limited stage small-cell lung cancer.
  • This report presents the results from a Mayo Clinic initiated phase I/II study exploring a potentially more aggressive local and systemic approach for treatment of limited-stage small-cell lung cancer (LSSCLC).
  • Five patients with LSSCLC received three cycles of induction cyclophosphamide, etoposide, and infusion cisplatin chemotherapy.
  • This was followed by accelerated hyperfractionated thoracic radiotherapy (AHFTRT) consisting of 30 Gy given as 1.5-Gy fractions twice daily with a 2-week break and then the AHFTRT was repeated.
  • After completion of the AHFTRT, patients received 4 cycles of oral etoposide maintenance chemotherapy.
  • No patients completed the entire protocol because of toxicity or progression during treatment.
  • There were two recurrences within the irradiated field, and distant metastases developed in four patients.
  • Acute nonlymphocytic leukemia developed in one patient, who died 2 months later.
  • No patient completed the entire protocol, because of toxicity or progression; therefore, this protocol cannot be recommended for the treatment of LSSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / prevention & control. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose Fractionation. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801753.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


69. Saijo N: Is radiotherapy optimally combined with chemotherapy in elderly patients with limited-stage small-cell lung cancer? Nat Clin Pract Oncol; 2005 Nov;2(11):550-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is radiotherapy optimally combined with chemotherapy in elderly patients with limited-stage small-cell lung cancer?
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Small Cell. Cisplatin / therapeutic use. Etoposide / therapeutic use. Lung Neoplasms
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270094.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Stathopoulos GP, Dimitroulis J, Toubis M, Katis C, Karaindros D, Stathopoulos J, Koutandos J: Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial. Lung Cancer; 2007 Jul;57(1):66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial.
  • Pemetrexed, a novel multi-targeted agent established for the treatment of mesothelioma, has been under investigation for other malignancies, and in recent years particularly for non-small-cell lung cancer (NSCLC).
  • In the present trial we investigated pemetrexed in combination with paclitaxel as front-line treatment in advanced or metastatic NSCLC.
  • There were 39 males and nine females, median age 62 years (range 37-81 years), one patient stage IIIA N(2), 23 patients, IIIB and 24, stage IV.
  • All patients had a cytologically- or histologically-confirmed diagnosis.
  • A 39.6% partial response rate was observed with a median survival of 14 months.
  • The combination of pemetrexed and paclitaxel at doses of 500mg/m(2) and 175mg/m(2), respectively, has been shown to be an effective combination with very limited toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alopecia / chemically induced. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / toxicity. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / toxicity. Asthenia / chemically induced. Female. Follow-Up Studies. Glutamates / administration & dosage. Glutamates / toxicity. Guanine / administration & dosage. Guanine / analogs & derivatives. Guanine / toxicity. Humans. Male. Middle Aged. Nausea / chemically induced. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Paclitaxel / administration & dosage. Paclitaxel / toxicity. Pemetrexed. Survival Analysis. Time Factors. Vomiting / chemically induced

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382431.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


71. Simon GR, Wagner H, American College of Chest Physicians: Small cell lung cancer. Chest; 2003 Jan;123(1 Suppl):259S-271S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell lung cancer.
  • Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade.
  • SCLC is staged as limited-stage disease and extensive-stage disease.
  • Standard staging procedures for SCLC include CT scans of the chest and abdomen, bone scan, and CT scan or MRI of the brain.
  • The role for positron emission tomography scanning in the staging of SCLC has yet to be defined.
  • Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure.
  • The median survival time for patients with limited-stage disease is approximately 18 months.
  • Extensive-stage disease is treated primarily with chemotherapy, with a high initial response rate of 60 to 70% and a complete response rate of 20 to 30%, but with a median survival time of approximately 9 months.
  • Currently, there is no role for maintenance treatment or bone marrow transplantation in the treatment of patients with SCLC.
  • Relapsed or refractory SCLC has a uniformly poor prognosis.
  • In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Brain Neoplasms / prevention & control. Brain Neoplasms / secondary. Combined Modality Therapy. Cranial Irradiation. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Neoplasm Staging. Radiotherapy Dosage. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527584.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Guideline; Journal Article; Practice Guideline; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 103
  •  go-up   go-down


72. Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM, Hainsworth J, McCune DE, Shukla R, Zeigler H, Hurtubise P, Chowdhury TR, Fletcher B, Dyehouse K, Ghalie R, Jazieh AR: A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol; 2009 Jun;32(3):269-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.
  • The aim of this study was to evaluate the efficacy and safety of denileukin diftitox in the treatment of advanced relapsed nonsmall cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Multicenter phase II trial in patients with NSCLC with Eastern Cooperative Oncology Group PS 0-2, stage IIIB/IV at diagnosis, who had failed at least 1 previous chemotherapy regimen.
  • RESULTS: For the 41 patients enrolled, the median age was 56 years (range, 21-80), 25 were men, and the median number of previous chemotherapy regimens was 2 (range, 1-5).
  • The median number of treatment cycles was 2 (range, 1-6).
  • By RECIST criteria, 18 (44%) had stable disease, 10 (24%) progressive disease, and 13 (32%) were not evaluable for response as they received less than 2 treatment cycles.
  • The median time to disease progression was 1.8 months [range, 0.3-11.3; 95% confidence interval (CI) 1.3-2.6].
  • The median follow-up time was 16.1 month.
  • One death from myocarditis verified at autopsy was attributed to treatment.
  • CONCLUSION: Denileukin diftitox at current dose schedule has limited activity in patients with previously treated NSCLC, manifested by disease control without impact on survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Resistance, Neoplasm. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Recombinant Fusion Proteins / therapeutic use. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433964.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


73. Collins LG, Haines C, Perkel R, Enck RE: Lung cancer: diagnosis and management. Am Fam Physician; 2007 Jan 1;75(1):56-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer: diagnosis and management.
  • Lung cancer is the leading cause of cancer-related death in the United States, with an average five-year survival rate of 15 percent.
  • Smoking remains the predominant risk factor for lung cancer.
  • Lung cancers are categorized as small cell carcinoma or non-small cell carcinoma (e.g., adenocarcinoma, squamous cell carcinoma, large cell carcinoma).
  • These categories are used for treatment decisions and determining prognosis.
  • Signs and symptoms may vary depending on tumor type and extent of metastases.
  • The diagnostic evaluation of patients with suspected lung cancer includes tissue diagnosis; a complete staging work-up, including evaluation of metastases; and a functional patient evaluation.
  • Histologic diagnosis may be obtained with sputum cytology, thoracentesis, accessible lymph node biopsy, bronchoscopy, transthoracic needle aspiration, video-assisted thoracoscopy, or thoracotomy.
  • Initial evaluation for metastatic disease relies on patient history and physical examination, laboratory tests, chest computed tomography, positron emission tomography, and tissue confirmation of mediastinal involvement.
  • Treatment and prognosis are closely tied to the type and stage of the tumor identified.
  • For stages I through IIIA non-small cell carcinoma, surgical resection is preferred.
  • Advanced non-small cell carcinoma is treated with a multimodality approach that may include radiotherapy, chemotherapy, and palliative care.
  • Chemotherapy (combined with radiotherapy for limited disease) is the mainstay of treatment for small cell carcinoma.
  • No major organization recommends screening for early detection of lung cancer, although screening has interested researchers and physicians.
  • [MeSH-major] Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225705.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


74. Castrucci WA, Knisely JP: An update on the treatment of CNS metastases in small cell lung cancer. Cancer J; 2008 May-Jun;14(3):138-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on the treatment of CNS metastases in small cell lung cancer.
  • Brain metastases occur frequently and are a significant threat to the quality of life in patients with small cell lung carcinoma.
  • The primary treatment modality has historically been whole brain radiation, which can provide a moderate extension of life and improvement in neurologic symptoms.
  • Despite increasing interest in the use of alternative therapeutic agents-primarily chemotherapy-these have yet to be demonstrated to be superior to radiation in management of brain metastasis.
  • Prophylactic cranial irradiation prevents or delays the occurrence of brain metastases in patients with small cell lung carcinoma.
  • Until recently, this benefit has been thought to be primarily restricted to a minority of patients with limited stage disease.
  • A large European trial, however, has now shown a survival benefit to the use of prophylactic cranial irradiation in patients who have any response to systemic chemotherapy.
  • This finding should significantly shift management practices for this aggressive disease for most patients.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Brain / drug effects. Brain / radiation effects. Cranial Irradiation. Humans. Neurotoxicity Syndromes / etiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536552.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


75. Sakai H, Yoneda S, Kobayashi K, Komagata H, Kosaihira S, Kazumoto T, Saito Y: Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer; 2004 Feb;43(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer.
  • The aim of this phase II study was to evaluate the efficacy and toxicity of DC with concurrent thoracic radiation therapy (TRT) followed by consolidation chemotherapy with DC for stage III unresectable non-small cell lung cancer (NSCLC).
  • Concurrent TRT was performed in 2-Gy daily fractions to a total dose of 60 Gy.
  • Median survival time by intention-to-treat analysis was 27 months, with survival rates of 76% at 1 year and 61% at 2 years.
  • Serious side effects were generally limited to grade 3 neutropenia in 6%, grades 3 and 4 pulmonary toxicity in 6 and 3%, respectively, and grade 3 esophagitis in 3% of patients.
  • CONCLUSIONS: DC with concurrent TRT followed by consolidation chemotherapy was highly active with manageable toxicity in patients with stage III unresectable NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2004 Nov;46(2):263-4 [15474675.001]
  • (PMID = 14739040.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


76. Yee D, Halperin R, Hanson J, Nijjar T, Butts C, Smylie M, Reiman T, Roa W: Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2006 Jun 1;65(2):466-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer.
  • PURPOSE: To determine the maximal tolerated dose of hypofractionated thoracic radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer patients.
  • Radiotherapy was given in two phases: patients initially received 20 Gy in 10 fractions to gross tumor plus uninvolved mediastinal nodes, followed by a boost to gross disease of 30, 38, or 42 Gy in 15 fractions.
  • All patients received four cycles of cisplatin (25 mg/m2) and etoposide (100 mg/m2) chemotherapy.
  • Radiotherapy commenced with Day 1 of Cycle 2 of chemotherapy.
  • There were no treatment-related deaths.
  • There was one Grade 3 acute nonhematologic toxicity in the 50-Gy group.
  • Of the 6 patients given 58 Gy, 3 experienced acute Grade 3 esophagitis.
  • With a median follow-up of 7 months, median overall survival was 9.5 months.
  • CONCLUSIONS: The maximal tolerated dose of thoracic radiotherapy with concurrent chemotherapy on this trial was 50 Gy in 25 daily fractions.
  • [MeSH-major] Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy. Maximum Tolerated Dose
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Radiotherapy, Conformal / adverse effects. Radiotherapy, Conformal / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563653.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


77. Uno T, Sumi M, Ishihara Y, Numasaki H, Mitsumori M, Teshima T, Japanese PCS Working Subgroup of Lung Cancer: Changes in patterns of care for limited-stage small-cell lung cancer: results of the 99-01 patterns of care study-a nationwide survey in Japan. Int J Radiat Oncol Biol Phys; 2008 Jun 1;71(2):414-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in patterns of care for limited-stage small-cell lung cancer: results of the 99-01 patterns of care study-a nationwide survey in Japan.
  • BACKGROUND: This study was undertaken to analyze the practice process of thoracic radiotherapy (TRT) and evaluate changes in patterns of care for patients with limited-stage small-cell lung cancer (LS-SCLC) in Japan.
  • METHODS AND MATERIALS: The Patterns of Care Study (PCS) conducted the second nationwide survey of care process for patients with LS-SCLC treated by using TRT between 1999 and 2001.
  • RESULTS: The PCS collected data for 139 patients with LS-SCLC (man-woman ratio, 5:1; median age, 69 years; age > 70 years, 43%; Karnofsky Performance Status > 70, 73%; and Stage III, 88%).
  • Median total dose was 50 Gy.
  • Three-dimensional conformal therapy was used with 12% of patients.
  • Computed tomography simulation was performed in 40% of cases.
  • Concurrent chemotherapy and TRT (CCRT) was used for 94 patients (68%).
  • Compared with the previous PCS 95-97, significant increases in the use of CCRT (34-68%; p < 0.0001), twice-daily TRT (15-44%; p < 0.0001), and PCI (1.7-8.6%; p =0.0045) were observed, although the absolute number of patients receiving PCI was still extremely low.
  • [MeSH-major] Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy. Practice Patterns, Physicians'
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Computer Simulation. Cranial Irradiation. Female. Health Care Surveys. Humans. Japan. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Staging. Radiation Oncology / standards. Radiation Oncology / trends. Radiotherapy / methods. Radiotherapy / standards. Radiotherapy, Conformal. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164865.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR: Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer; 2005 Jul;7(1):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
  • BACKGROUND: This phase II cooperative group study of patients with unresectable stage III non-small-cell lung cancer was designed to treat patients with induction chemotherapy with paclitaxel and carboplatin (PC) followed by concurrent chemotherapy with the same chemotherapy plus thoracic irradiation to 66 Gy.
  • The eligibility criteria allowed treatment of an expanded population of patients, unrestricted by previous weight loss.
  • The 3-year overall survival rate is consistent with landmark cooperative group results for the combined modality treatment of a more highly selected patient population.
  • CONCLUSION: The feasibility of this therapeutic approach in a cooperative group setting and inclusive of patients who were representative of the general population of stage III lung cancer patients was established.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098244.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 03927; United States / NCI NIH HHS / CA / CA 08025; United States / NCI NIH HHS / CA / CA 12046; United States / NCI NIH HHS / CA / CA 12449; United States / NCI NIH HHS / CA / CA 21060; United States / NCI NIH HHS / CA / CA 31946; United States / NCI NIH HHS / CA / CA 45808; United States / NCI NIH HHS / CA / CA 47642
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; PC protocol
  •  go-up   go-down


79. Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA: Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res; 2004 Jun 15;10(12 Pt 2):4205s-4209s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
  • Bronchioloalveolar carcinoma (BAC) is a previously uncommon subset of non-small cell lung cancer (NSCLC) with unique epidemiology, pathology, clinical features, radiographic presentation, and natural history compared with other NSCLC subtypes.
  • Limited data suggest that chemotherapy may yield poor results in BAC.
  • Here we present clinical data and preliminary results of correlative science studies analyzing human epidermal growth factor receptor pathways from the following two prospective Southwest Oncology Group clinical trials performed in advanced stage BAC: S9714 testing a 96-h continuous infusion of paclitaxel (Taxol) and S0126 evaluating the small molecule EGFR inhibitor gefitinib (ZD1839 or Iressa).
  • These studies provide a biological rationale for investigating BAC as a model of predictive markers of EGFR inhibition.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / physiopathology. Biomarkers, Tumor / analysis. Lung Neoplasms / physiopathology. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / physiology
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Clinical Trials as Topic. Humans. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use. Prognosis. Quinazolines / administration & dosage. Quinazolines / therapeutic use. Signal Transduction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217959.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CM / N01-CM17101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; P88XT4IS4D / Paclitaxel; S65743JHBS / gefitinib
  • [Number-of-references] 19
  •  go-up   go-down


80. Vallières E: Role of adjuvant systemic therapy for stage I NSCLC. Thorac Surg Clin; 2007 May;17(2):279-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of adjuvant systemic therapy for stage I NSCLC.
  • Based on the limited data presented, in North America and in Europe. one cannot recommend the routine use of adjuvant systemic chemotherapy after the complete resection of stages IA and IB NSCLC.
  • The data from Japan are certainly intriguing and bring a potentially new adjuvant strategy for these patients: low-dose, long-term, well-tolerated adjuvant oral therapy.
  • One also realizes that not every resected stage I tumor carries the same prognosis, a fact that most trials have not taken into consideration.
  • Despite the lack of trial results to support adjuvant chemotherapy in stage IA and IB diseases, however, outside of a clinical trial setting, it is probably reasonable to consider the possibility of adjuvant systemic chemotherapy in the individualized healthy younger patient whose resected tumor exhibited poor prognostic histologic findings, such as lymphovascular invasion, larger size, or even high fluorodeoxyglucose avidity on preoperative positron emission tomography scan.
  • Ideally, however, these patients should all be considered to participate in the next generation of trials exploring the strategy of adjuvant therapy in the management of completely resected stage I NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoplasm Staging. Pneumonectomy. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626406.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 18
  •  go-up   go-down


81. Fukuoka M, Kurata T, Yamamoto N: [Evidence-based practice guideline for unresectable advanced lung cancer in 2003]. Nihon Geka Gakkai Zasshi; 2004 Jul;105(7):412-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evidence-based practice guideline for unresectable advanced lung cancer in 2003].
  • Recently evidence-based practice guideline for lung cancer in 2003 has been published.
  • Recommendations for the treatment of unresectable non-small cell and small cell lung cancer are described here.
  • Cisplatin-based chemotherapy combined with thoracic radiotherapy is recommended for the treatment for unresectable stage III non-small cell lung cancer.
  • New chemotherapy agents, including paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan have been incorporated into combination regimens with carboplatin or cisplatin have become the standard therapy for advanced/metastatic NSCLC.
  • Docetaxel is recommended as second-line therapy for patients with locally advanced or metastatic NSCLC who have progressed on first-line therapy.
  • Etopside and cisplatin concurrently combined with twice-daily thoracic radiotherapy (TRT) is the standard care of limited -disease small cell lung cancer (SCLC).
  • Recent randomized controlled trial demonstrated that irinotecan and cisplatin is superior to etoposide and cisplatin, a standard treatment of extensive-disease SCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Evidence-Based Medicine. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Practice Guidelines as Topic
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15303441.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


82. Hermes A, Gatzemeier U, Waschki B, Reck M: Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis. Respir Med; 2010 Dec;104(12):1937-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis.
  • PURPOSE: The aim of this retrospective study is to present data on clinical significance of lactate dehydrogenase (LDH) serum levels in an unselected contemporary patient population with small cell lung cancer (SCLC) in limited disease (LD) and extensive disease stage (ED).
  • PATIENTS AND METHODS: From June 2004 to June 2008, our electronic database including all in-patient and out-patient contacts was searched for patients with newly diagnosed LD and ED SCLC.
  • We collected data on patient characteristics including clinical performance status and LDH serum levels, metastatic sites, efficacy of first line chemotherapy and survival.
  • RESULTS: In both limited and extensive disease SCLC, elevated LDH serum levels resulted in significantly shorter median survival.
  • In patients with limited disease and normal LDH levels, median survival was 18.0 months.
  • In cases with extensive disease, overall survival was significantly lower in patients with elevated LDH serum levels with an additional reduction in overall survival in patients with LDH levels above 300 U/l. (7.0 vs. 12.0 months, p = <0.001).
  • Multivariate Cox regression analyses revealed LDH levels to be an independent predictor of mortality after adjustment for age and Performance Status in LD and ED SCLC (HR 1.003, p = 0.017; HR 1.001, p = 0.002 respectively).
  • However, categorizing LDH levels revealed no significant difference in LD SCLC.
  • CONCLUSION: In our contemporary comprehensive patient population, LDH is proved to be a strong, independent predictive factor of median survival in patients with LD and ED SCLC.
  • [MeSH-major] Carcinoma, Small Cell / pathology. L-Lactate Dehydrogenase / blood. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20719490.001).
  • [ISSN] 1532-3064
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


83. Hanna NH, Einhorn LH: Small-cell lung cancer: state of the art. Clin Lung Cancer; 2002 Sep;4(2):87-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell lung cancer: state of the art.
  • Thirty years ago, there was a pervasive atmosphere of pessimism concerning the management of small-cell lung cancer (SCLC).
  • Surgery or radiation therapy alone resulted in few cures since these techniques utilize a local therapy for a disseminated disease.
  • Chemotherapy remains the backbone of treatment for all patients with SCLC, regardless of stage.
  • For patients with limited-stage disease (LD), the addition of thoracic radiation to chemotherapy is standard.
  • While phase III trials have failed to demonstrate a statistically significant survival for PCI, brain relapse is clearly reduced, and a metaanalysis reports a small long-term survival advantage favoring patients receiving PCI.
  • Unfortunately, unlike LD SCLC, advances in extensive-stage disease have been elusive, despite the testing of numerous strategies.
  • Four courses of cisplatin (or carboplatin) plus etoposide remain standard first-line therapy.
  • A plateau has been reached with chemotherapy regimens, and novel strategies are greatly needed to improve survival for patients with SCLC.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14653864.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Stoelben E, Huber RM, Müller RP, Wolf J: [Multimodality therapy for lung cancer]. Internist (Berl); 2010 Nov;51(11):1348-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multimodality therapy for lung cancer].
  • [Transliterated title] Multimodale Therapie des Lungenkarzinoms.
  • The primary treatment of lung cancer depends on tumor stage.
  • In case of lung cancer in clinical stage I to IIb and T3N1 surgical treatment is recommended.
  • The use of adjuvant chemotherapy is indicated in stage II and IIIa.
  • In case of limited N2-disease trimodality therapy with chemo- or radiochemotherapy followed by surgery and eventual adjuvant radiotherapy leads to five year survival rate of about 20-40.
  • If the tumor has infiltrated the mediastinum or the upper sulcus (T3/4) or in case of solitary metastasis an individual trimodal treatment plan has to be elaborated.
  • Also for small cell lung cancer surgery combined with chemotherapy can be applied in stage I and II, else and especially in stage III radiochemotherapy should be applied.
  • The majority of lung cancer patients suffers from metastatic disease.
  • The value of systemic chemotherapy is limited with significant, but small improvement in overall survival.
  • Also treatment with the new molecularly targeted drugs does not result in a breakthrough in unselected patient cohorts.
  • Recently, substantial progress could be achieved by personalized treatment approaches for patients harbouring special genetic alterations.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Diagnostic Imaging. Humans. Neoadjuvant Therapy. Neoplasm Staging. Practice Guidelines as Topic. Precision Medicine. Prognosis. Randomized Controlled Trials as Topic. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] Eur J Cardiothorac Surg. 2009 Mar;35(3):450-6 [19188079.001]
  • [Cites] Eur Respir J. 2009 Jul;34(1):17-41 [19567600.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Nuklearmedizin. 2009;48(2):59-69, quiz N8-9 [19333516.001]
  • [Cites] Lancet. 2009 Aug 1;374(9687):379-86 [19632716.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):442-50 [17374834.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • (PMID = 20967407.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


85. Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT 3rd, Sharma AK: Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol; 2010 Jun;28(5):340-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes.
  • PURPOSE: The aim of this study was to compare toxicities, disease control, survival outcomes, and patterns of failure between groups of limited-stage small-cell lung cancer patients treated with once-daily versus twice-daily radiotherapy and concurrent chemotherapy.
  • MATERIALS AND METHODS: This single-institution retrospective analysis included a comparison of two of radiotherapy regimens to planned doses of (1) > or =59.4 Gy at 1.8-2.0 Gy per once-daily fraction or (2) > or =45 Gy at 1.5 Gy per twice-daily fractions with concurrent platinum-based chemotherapy.
  • Comparative analyses of toxicities and disease control were performed.
  • Patient, tumor, staging, and treatment factors were similar between the two treatment groups.
  • Median planned radiotherapy doses were 60 Gy (range 59.4-70.0 Gy) and 45 Gy (range 45-51 Gy) for the once-daily and twice-daily groups, respectively.
  • CONCLUSION: The present analysis did not detect a statistically significant difference in acute toxicities, disease control, or survival outcomes in limited-stage small-cell lung cancer patients treated with concurrent chemotherapy and once-daily versus twice-daily radiotherapy.
  • [MeSH-major] Lung Neoplasms / therapy. Radiotherapy Dosage. Small Cell Lung Carcinoma / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1106-13 [15001251.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4553-9 [14597743.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1618-24 [1331787.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72 (2):327-34 [18793952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):342-50 [15890573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):100-7 [16839700.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3528-36 [9817271.001]
  • [Cites] Chest. 2000 Feb;117(2):358-64 [10669675.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5910-7 [16087956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):993-8 [3036753.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):414-9 [18164865.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):265-71 [9920950.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):307-12 [16949169.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):890-5 [1316951.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1108-13 [19084345.001]
  • (PMID = 20585921.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Japan
  •  go-up   go-down


86. Huncharek M, McGarry R: A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist; 2004;9(6):665-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer.
  • The objective of this study was to determine whether initial combined chemoradiation results in superior 1-, 2-, and 3-year survivals in the treatment of limited-stage small cell lung cancer versus sequential or split-course therapy.
  • Pooling data from eight randomized controlled trials enrolling over 1,500 patients showed that early integration of chest radiotherapy with systemic chemotherapy increases overall survival by 34%-216%, depending on the end point of interest.
  • Etoposide (E) plus cisplatin (P) in conjunction with chest irradiation appears to offer the greatest increase in survival versus delayed or split-course radiation therapy and non-EP-containing drug schedules.
  • The available randomized trial data support early concurrent chest radiotherapy and systemic chemotherapy in the form of E and P in the management of limited-stage small cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / mortality. Lung Neoplasms / therapy
  • [MeSH-minor] Humans. Radiotherapy Dosage. Radiotherapy, Adjuvant / methods. Randomized Controlled Trials as Topic. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15561810.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


87. Lee SH, Ahn YC, Kim HJ, Lim DH, Lee SI, Nam E, Park SH, Park J, Lee KE, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park K: Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer. Jpn J Clin Oncol; 2003 Dec;33(12):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer.
  • BACKGROUND: Combined chemoradiotherapy (CRT) is the standard treatment modality for limited-stage small-cell lung cancer (LSCLC), but the optimal timing of radiation is controversial.
  • We conducted a phase II trial of early concurrent CRT, starting from the very beginning of the first cycle of chemotherapy for previously untreated LSCLC.
  • METHODS: Chemotherapy was given for six cycles, each consisting of oral etoposide (50 mg/m(2) daily from day 1 to 14) and intravenous cisplatin (75 mg/m(2) on day 1), every 3 weeks.
  • Thoracic radiation therapy was given from day 1 of the first cycle of chemotherapy, administered at 2.0 Gy in 22 daily fractions to a total dose of 44 Gy.
  • Median overall survival was 14.9 months (95% CI, 11.4-18.3 months) and the median time to progression was 10.8 months (95% CI, 9.3-12.4 months) for the ITT population.
  • CONCLUSIONS: Early concurrent CRT, starting from the very beginning of the first cycle of chemotherapy with prolonged oral etoposide and cisplatin failed to show any improvement in survival compared with other CRT regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged


88. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature; 2007 Dec 20;450(7173):1235-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of rare circulating tumour cells in cancer patients by microchip technology.
  • Viable tumour-derived epithelial cells (circulating tumour cells or CTCs) have been identified in peripheral blood from cancer patients and are probably the origin of intractable metastatic disease.
  • Although extremely rare, CTCs represent a potential alternative to invasive biopsies as a source of tumour tissue for the detection, characterization and monitoring of non-haematologic cancers.
  • The ability to identify, isolate, propagate and molecularly characterize CTC subpopulations could further the discovery of cancer stem cell biomarkers and expand the understanding of the biology of metastasis.
  • Current strategies for isolating CTCs are limited to complex analytic approaches that generate very low yield and purity.
  • Here we describe the development of a unique microfluidic platform (the 'CTC-chip') capable of efficient and selective separation of viable CTCs from peripheral whole blood samples, mediated by the interaction of target CTCs with antibody (EpCAM)-coated microposts under precisely controlled laminar flow conditions, and without requisite pre-labelling or processing of samples.
  • The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 (99%) samples, with a range of 5-1,281 CTCs per ml and approximately 50% purity.
  • In addition, CTCs were isolated in 7/7 patients with early-stage prostate cancer.
  • Given the high sensitivity and specificity of the CTC-chip, we tested its potential utility in monitoring response to anti-cancer therapy.
  • In a small cohort of patients with metastatic cancer undergoing systemic treatment, temporal changes in CTC numbers correlated reasonably well with the clinical course of disease as measured by standard radiographic methods.
  • Thus, the CTC-chip provides a new and effective tool for accurate identification and measurement of CTCs in patients with cancer.
  • It has broad implications in advancing both cancer biology research and clinical cancer management, including the detection, diagnosis and monitoring of cancer.


89. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol; 2004 Dec 1;22(23):4837-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.
  • PURPOSE: We employed meta-analytic techniques to evaluate early (E) versus late (L) timing of thoracic radiation therapy (RT) in limited-stage small-cell lung cancer (LS-SCLC).
  • METHODS: Randomized trials published after 1985 addressing timing of RT relative to chemotherapy in LS-SCLC were included.
  • RESULTS: Overall survival (OS) RRs for all studies were 1.17 at 2 years (95% CI, 1.02 to 1.35; P = .03) and 1.13 at 3 years (95% CI, 0.92 to 1.39; P = .2), indicating a significantly increased 2-year survival for ERT versus LRT patients and suggestive of a similar trend at 3 years.
  • Studies using platinum-based chemotherapy had OS RRs of 1.30 (95% CI, 1.10 to 1.53; P = .002) and 1.35 (95% CI, 1.07 to 1.70; P = .01) at 2 and 3 years, respectively, favoring ERT.
  • Studies using nonplatinum-based chemotherapy regimens had nonsignificant differences in OS.
  • CONCLUSION: A small but significant improvement in 2-year OS for ERT versus LRT in LS-SCLC was observed, similar to the benefit of adding RT to chemotherapy or prophylactic cranial irradiation.
  • A greater difference was evident for hyperfractionated RT and platinum-based chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Confidence Intervals. Dose Fractionation. Dose-Response Relationship, Radiation. Humans. Neoplasm Staging. Odds Ratio. Pneumonectomy / methods. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2005 Jan 1;23(1):248
  • (PMID = 15570087.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


90. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P: Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev; 2007 Aug;33(5):461-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.
  • BACKGROUND: We undertook a systematic review and literature-based meta-analysis to determine whether the timing of chest radiotherapy may influence the survival of patients with limited stage small cell lung cancer (LS-SCLC).
  • OBJECTIVES: To establish the most effective way of combining chest radiotherapy with chemotherapy for patients with limited-stage small cell lung cancer in order to improve long-term survival.
  • MATERIALS: Eligible studies were identified according to the Cochrane Collaboration Guidelines and were randomised controlled clinical trials comparing different timing of chest radiotherapy in patients with LS-SCLC.
  • Early chest irradiation was defined as beginning within 30 days after the start of chemotherapy.
  • When only trials were considered that used platinum chemotherapy concurrent with chest radiotherapy, significantly higher 2 and 5-year survival rates were observed when chest radiotherapy (RT) was started within 30 days after the start of chemotherapy (2-year survival: HR: 0.73, 95% CI 0.57-0.94, p=0.01; 5-year survival: HR: 0.65, 95% CI 0.45-0.93, p=0.02).
  • This was even more pronounced when the overall treatment time of chest radiotherapy was less than 30 days.
  • In studies that did not show a survival advantage by early chest radiation, a lower dose-intensity of chemotherapy in the early vs. late arm was observed.
  • CONCLUSIONS: When platinum-based chemotherapy concurrently with chest RT is used, the 2- and 5-year survival rates of patients with LS-SCLC may be in favour of early chest radiotherapy, with a significant difference if the overall treatment time of chest radiation is less than 30 days.
  • [MeSH-major] Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy. Thorax / radiation effects
  • [MeSH-minor] Humans. Neoplasm Staging. Randomized Controlled Trials as Topic. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513057.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 27
  •  go-up   go-down


91. Kurup A, Hanna NH: Treatment of small cell lung cancer. Crit Rev Oncol Hematol; 2004 Nov;52(2):117-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of small cell lung cancer.
  • The incidence of small cell lung cancer (SCLC) is declining in the United States (US).
  • SCLC is nearly universally smoking-related and is very sensitive to both chemotherapy and radiation therapy.
  • In contrast to non-small cell lung cancer (NSCLC), SCLC is staged as either limited-stage disease (LD) or extensive-stage disease (ED).
  • Chemotherapy remains the essential component for treatment of all patients with SCLC, regardless of stage or performance status.
  • In LD, the addition of radiation therapy improves survival over chemotherapy alone.
  • Many chemotherapy agents and combinations result in high response rates in ED SCLC; however, median survival time remains 8-10 months.
  • Patients with ED frequently relapse, and relapsed/refractory SCLC has a poor prognosis.
  • The challenge remains to identify novel therapies and molecular targets to improve survival in SCLC.
  • [MeSH-major] Carcinoma, Small Cell / therapy
  • [MeSH-minor] Brain Neoplasms / mortality. Brain Neoplasms / prevention & control. Brain Neoplasms / secondary. Combined Modality Therapy. Humans. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15501076.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 96
  •  go-up   go-down


92. Xie L, Ugnat AM, Morriss J, Semenciw R, Mao Y: Histology-related variation in the treatment and survival of patients with lung carcinoma in Canada. Lung Cancer; 2003 Nov;42(2):127-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology-related variation in the treatment and survival of patients with lung carcinoma in Canada.
  • OBJECTIVES: The aim of the study was to examine histologic differences in lung cancer treatment and survival, and to define recent survival trends in Ottawa, Canada.
  • METHODS: From 1994 to 2000, 3,237 patients with invasive lung cancer were registered at the Ottawa Regional Cancer Centre (ORCC) and were followed up to 31 December 2001.
  • Five-year relative survival rates (RSRs) and relative excess risks (RERs) of dying were calculated by stage and dominant initial treatment modalities for major cellular histologies using a relative survival model.
  • Patients with stage I and II non-small cell lung cancer (NSCLC) who were treated by surgery alone were more likely to survive (5-year RSRs were 72 and 48%, respectively) than those who received other treatments.
  • Patients with stage III NSCLC had a 5-year survival rate of 9% after chemotherapy plus radiotherapy, whereas stage IV patients who received only chemotherapy had better survival for up to 2 years than patients with other treatments.
  • In cases of limited-stage small cell lung cancer (SCLC), survival was better for patients who received chemotherapy plus radiotherapy than for those who received only chemotherapy.
  • CONCLUSIONS: The relatively superior survival of surgical patients with stage I NSCLC implies that a considerable number of patients have the potential to be treated successfully.
  • The overall poor survival of lung cancer patients suggests a need for more national public health emphasis on lung cancer prevention, improved screening and early diagnosis, and better treatment.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Small Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2004 Jul;45(1):125; author reply 127 [15196743.001]
  • (PMID = 14568680.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


93. Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S: Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Lung Cancer; 2010 Jun;68(3):450-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
  • PURPOSE: The combination of irinotecan and cisplatin (IP) has shown at least comparable efficacy to that of etoposide/cisplatin (EP) in patients with extensive-stage small cell lung cancer.
  • We conducted a phase II study to evaluate the efficacy and tolerance of EP regimen followed by thoracic radiotherapy (TRT) and IP consolidation chemotherapy in patients with limited-stage small cell lung cancer.
  • PATIENTS AND METHODS: Thirty-three chemotherapy-naive patients with limited-stage small cell lung cancer (LS-SCLC) were treated with etoposide 100mg/m(2) on days 1-3 and cisplatin 80mg/m(2) on day 1.
  • Radiotherapy was given 3 weeks after the first treatment cycle concurrently with weekly cisplatin 20mg/m(2) on day 1 and etoposide 50mg/m(2) on day 4 within 5-6 weeks, followed by three courses of irinotecan 60mg/m(2) on days 1, 8, and 15 and cisplatin 60mg/m(2) on day 1 of a 4-week cycle.
  • RESULTS: There were no treatment-related deaths.
  • The major toxicity observed during consolidation chemotherapy was grades 3-4 neutropenia which affected 42% of patients.
  • After a median follow-up period of 35.7 months (range: 9.6-41.2 months), the median survival time was 19 months (95% CI: 14.5-23.5 months), the median time to tumor progression 8.3 months and the 1- and 2-year survival rates 72% and 27.5%, respectively.
  • CONCLUSIONS: Consolidation chemotherapy with IP following concurrent EP plus TRT is a safe and with acceptable toxicity regimen and deserves further phase III testing in patients with LS-SCLC.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Small Cell Lung Carcinoma / drug therapy. Small Cell Lung Carcinoma / radiotherapy
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Therapy, Combination. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / etiology. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19783319.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


94. Garst J, Herndon JE 2nd, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J: A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Clin Drug Investig; 2006;26(5):257-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
  • OBJECTIVE: To determine the feasibility and maximum tolerated dose of dose-dense topotecan as induction chemotherapy before standard therapy (carboplatin plus etoposide alone or in combination with radiotherapy) in patients with small cell lung cancer (SCLC).
  • PATIENTS AND METHODS: Chemotherapy-naive patients with SCLC and good performance status were eligible.
  • Three 2-week cycles of dose-dense topotecan administered on days 1-3 with granulocyte colony-stimulating factor support were followed by four cycles of standard carboplatin plus etoposide therapy alone (extensive-stage SCLC) or with radiotherapy (limited-stage SCLC).
  • Dose-limiting toxicity was defined as any grade 3 or 4 toxicity resulting in a treatment reduction or a delay of >3 days.
  • RESULTS: Twenty-two patients with SCLC (5 limited-stage, 17 extensive-stage) were enrolled.
  • Treatment was well tolerated.
  • The dose-limiting toxicities were thrombocytopenia and neutropenia, and the maximum tolerated dose of dose-dense topotecan induction therapy was 2.25 mg/m2/day.
  • Toxicity during the carboplatin plus etoposide +/- radiotherapy phase of therapy was consistent with that reported in previous trials.
  • The overall response rate was 80% for limited-stage and 76% for extensive-stage SCLC.
  • Median survival was 8 months in patients with limited-stage SCLC and 13.5 months for patients with extensive-stage SCLC.
  • CONCLUSION: The results of this phase I study suggest that a regimen of sequential dose-dense topotecan and carboplatin plus etoposide is feasible, and the preliminary activity observed in patients with SCLC warrants further investigation at a starting dose of topotecan 2.25 mg/m2/day.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Anorexia / chemically induced. Carboplatin / administration & dosage. Carboplatin / adverse effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematologic Diseases / chemically induced. Humans. Karnofsky Performance Status. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Remission Induction. Survival Rate. Topotecan / administration & dosage. Topotecan / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1987 May;106(5):655-62 [3032033.001]
  • [Cites] N Engl J Med. 1987 Apr 9;316(15):912-8 [3029592.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] CA Cancer J Clin. 2000 May-Jun;50(3):171-83 [10901740.001]
  • [Cites] Cancer Treat Rep. 1977 May-Jun;61(3):349-54 [194691.001]
  • [Cites] J Clin Oncol. 1987 Nov;5(11):1731-8 [2824707.001]
  • [Cites] J Clin Oncol. 1985 Jan;3(1):54-64 [2981292.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] Oncologist. 2002;7(3):234-8 [12065796.001]
  • [Cites] Semin Radiat Oncol. 1995 Jan;5(1):33-39 [10717123.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):777-82 [11395247.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2022-34 [7931470.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):56-70 [12908137.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):101-7 [12672038.001]
  • [Cites] Lung Cancer. 2002 Jul;37(1):79-85 [12057871.001]
  • [Cites] N Engl J Med. 1993 Dec 16;329(25):1848-52 [8247036.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2345-52 [8708727.001]
  • (PMID = 17163259.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin
  •  go-up   go-down


95. Ohe Y: Chemoradiotherapy for lung cancer. Expert Opin Pharmacother; 2005 Dec;6(16):2793-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy for lung cancer.
  • Chemoradiotherapy is a standard treatment for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer.
  • Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced non-small cell lung cancer.
  • The state-of-the-art treatment for limited-stage small cell lung cancer is four cycles of chemotherapy with cisplatin plus etoposide combined with early concurrent twice-daily thoracic irradiation and prophylactic cranial irradiation after complete remission.
  • A 5-year survival rate of approximately 25% is expected among patients treated for limited-stage small cell lung cancer.
  • The incorporation of new agents, including target-based drugs, is one of the most promising strategies for improving the survival of patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / radiotherapy. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318430.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 84
  •  go-up   go-down


96. Yau T, Ashley S, Popat S, Norton A, Matakidou A, Coward J, O'Brien ME: Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer. Br J Cancer; 2006 Jan 16;94(1):18-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer.
  • Platinum-based treatment for small cell lung cancer (SCLC) has been established since 1995.
  • This study investigates treatment outcome of elderly patients (age >/=70 years) with SCLC over the past 20 years in a large UK cancer centre.
  • Comparison of all-cause survival was assessed in patients presenting between two predefined time periods: 1982-1994 and 1995-2003.
  • All the survival analysis were adjusted for stage and performance status and age if appropriate.
  • Survival between different chemotherapy treatment regimens was compared.
  • A total of 322 elderly patients (31% of all) registered between 1982-2003 received chemotherapy for SCLC.
  • Patients presenting in 1995-2003 had an overall better median survival (43 vs 25 weeks) and a 1-year survival (37 vs 14%) than patients presenting in 1982-1994 (P<0.001).
  • This applied to patients with both limited and extensive stage disease and all age groups.
  • There was a trend towards the use of more platinum-based treatments in the later cohort but the use of radiotherapy remained constant.
  • Patients who received platinum combinations (Carboplatin or Cisplatin) had significantly improved survival over those who received single agents or other combinations (P<0.001) and there was no significant difference between carboplatin and cisplatin (P=0.7).
  • The analysis demonstrates that there has been a significant improvement in survival for elderly patients with lung cancer treated by chemotherapy in the past 20 years despite more very elderly patients being treated with a poorer performance status.
  • This change is probably multifactorial and may be due to the increased use of platinum-based treatment and improved supportive care.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):476-84 [10441603.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1953-60 [11064352.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):300-8 [11181777.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):808-15 [11556829.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18 Suppl):23S-33S [12235221.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4665-72 [12488411.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 5;95(5):341-3 [12618492.001]
  • [Cites] Cancer Chemother Rep 3. 1973 Mar;4(2):31-42 [4580860.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):344-54 [2537384.001]
  • [Cites] Thorax. 1989 Aug;44(8):631-3 [2477908.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1563-74 [2167954.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1618-24 [1331787.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):821-8 [8622030.001]
  • [Cites] Thorax. 1996 Jun;51(6):564-8 [8693434.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):563-6 [8774567.001]
  • [Cites] J Natl Cancer Inst. 1997 Apr 16;89(8):577-80 [9106647.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3323-8 [9779708.001]
  • [Cites] Chest. 2000 May;117(5):1239-46 [10807806.001]
  • (PMID = 16317431.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2361085
  •  go-up   go-down


97. Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K: A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs; 2006 May;24(3):213-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer.
  • Limited stage small cell lung cancer (LS-SCLC) is an infrequent but aggressive tumor.
  • No major advances in the treatment of this disease have been achieved in recent years.
  • This study was conducted to determine the maximum-tolerated dose (MTD) and efficacy of docetaxel, etoposide, and carboplatin (DEC) given before definitive chest radiotherapy with concurrent cisplatin and etoposide.
  • Seventeen untreated LS-SCLC patients received docetaxel 50 mg/m2, etoposide 50-80 mg/m2, and carboplatin AUC = 5-6, intravenously on day 1 followed by etoposide 100-160 mg/m2 orally on days 2 and 3 every 21 days for two cycles followed by once daily radiotherapy to a total dose of 50 Gy given concurrently with cisplatin (60 mg/m2, d1) and etoposide (120 mg/m2, d1 and 240 mg/m2 day 2-3) for 2 cycles.
  • This novel approach produced similar efficacy results to current two drug regimens but was associated with significant neutropenia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2000 Apr;117(4 Suppl 1):156S-162S [10777472.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):601-7 [7993835.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3532-8 [11481360.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3464-70 [9396399.001]
  • [Cites] Eur J Cancer. 1994;30A(8):1058-60 [7654428.001]
  • [Cites] Lung Cancer. 2003 Jan;39(1):77-84 [12499098.001]
  • [Cites] Invest New Drugs. 1996;13(4):343-5 [8824354.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):463-70 [11398877.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1618-24 [1331787.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2325-9 [11489808.001]
  • [Cites] Lung Cancer. 2003 Jan;39(1):63-9 [12499096.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-130-S12-134 [9331137.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):237-41 [10439170.001]
  • [Cites] Semin Oncol. 1995 Oct;22(5 Suppl 12):54-8; discussion 59-60 [7481862.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):265-71 [9920950.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):127-32 [14701775.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):890-5 [1316951.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3419-24 [10589753.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1102-9 [10694563.001]
  • (PMID = 16193241.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


98. Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK: Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol; 2010 Oct;54(5):483-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival.
  • INTRODUCTION: Major randomised trials have employed elective nodal irradiation as part of combined modality therapy for limited-stage small-cell lung cancer (SCLC).
  • The present investigation describes patterns of failure, disease control, and survival outcomes for involved-field radiotherapy with concurrent chemotherapy, without elective irradiation of uninvolved mediastinal nodal regions.
  • METHODS: Retrospective analysis of SCLC patients treated with curative-intent accelerated, twice-daily radiotherapy and concurrent platinum-based chemotherapy at an academic institution.
  • Treatment fields were reviewed, and patients who completed ≥42 Gy in 1.5 Gy twice-daily fractions to involved fields (without elective irradiation of uninvolved mediastinal lymphatic regions) were included in the present analysis.
  • Initial patterns of failure, disease control and overall survival were recorded.
  • All but one patient completed three to four cycles of chemotherapy, and 10 patients experienced grade 3 acute esophagitis.
  • At a median survivor follow-up of 35 months (range 5.5-91.9), 22 patients were alive (15 without recurrence) and 30 had died (23 of/with disease, four of unknown cause, two of other cause and one of treatment toxicity).
  • Initial site(s) of disease failure were loco-regional only (11 patients), distant only (14) and loco-regional plus distant (3).
  • There were no cases of isolated out-of-field mediastinal recurrence in the absence of supraclavicular or more distant disease.
  • The estimated 3-year disease-free and overall survivals were 36% and 44%, respectively.
  • CONCLUSIONS: Involved-field radiotherapy did not appear to have an adverse impact on the anticipated patterns of failure, disease control, or overall survival in this population of limited-stage SCLC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal of Medical Imaging and Radiation Oncology © 2010 The Royal Australian and New Zealand College of Radiologists.
  • (PMID = 20958948.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA120494
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


99. Ismaili N, Arifi S, Flechon A, El Mesbahi O, Blay JY, Droz JP, Errihani H: Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer; 2009 Jun;96(6):E30-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis.
  • Small cell carcinoma of the bladder (SCCB) is rare, highly aggressive and diagnosed mainly at advanced stages.
  • In addition, coexistence of SCCB with other types of carcinoma is common.
  • Histological tests show a tumour, which is indistinguishable from small cell lung carcinoma (SCLC).
  • Then immunohistochemistry tests may be helpful for a more precise diagnosis.
  • Pathogenesis is uncertain; however the multipotent stem cell theory applies best to this case.
  • The most common staging system used is the two-stage system (limited-extensive).
  • Because of the rarity of the disease, the management is extrapolated from that of SCLC.
  • Limited-stage disease should be treated with etoposide-cisplatin chemotherapy in combination either with radiotherapy, or surgery or both.
  • Extensive-stage disease should be managed by combined chemotherapy.
  • Further research programmes are needed to improve the diagnosis and the treatment of SCCB tumour.
  • This paper would provide a comprehensive review of the epidemiology, clinical features, diagnosis, pathologic features, histogenesis, molecular genetics, staging, treatment, and prognosis of SCCB.
  • [MeSH-major] Carcinoma, Small Cell. Urinary Bladder Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy / methods. Hematuria / etiology. Humans. Immunohistochemistry / methods. Neoplasm Staging / methods. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457759.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 70
  •  go-up   go-down


100. Brade AM, Tannock IF: Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol; 2006 Mar 1;24(7):1020-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure?
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Neoplastic Cells, Circulating / drug effects. Neoplastic Cells, Circulating / radiation effects
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Dose Fractionation. Drug Administration Schedule. Humans. Neoadjuvant Therapy / methods. Radiotherapy, Adjuvant / methods. Randomized Controlled Trials as Topic. Treatment Failure

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Aug 20;24(24):3815-6 [16921030.001]
  • [CommentOn] J Clin Oncol. 2006 Mar 1;24(7):1052-6 [16505423.001]
  • (PMID = 16505418.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down






Advertisement